Trading Analysis Report: AMD¶

Generated: 2026-10-02 09:18:42

I. Analyst Team Reports¶

Market Analyst¶

Current Price: 615.73 Price As Of: 2026-10-01

AMD (Advanced Micro Devices, Inc., NMS): Technical Report as of 2026-10-01¶

1. Indicators chosen and why¶

I picked indicators that don't overlap: one or two per job.

Role	Indicators	Why
Trend structure	close_50_sma, close_200_sma, close_10_ema, supertrend (weekly, monthly, daily)	AMD is in a steep multi-month advance. I need to know how far price sits above each average and where the trailing stops are.
Trend strength	adx	The September breakout may be fading in intensity, and ADX measures that.
Momentum	rsi, macd, macds, macdh	They show whether momentum is still supportive without being extreme.
Volatility	boll, boll_ub, boll_lb, atr	Price has moved fast, so band width and ATR matter for stop distance and position size.
Volume	obv, mfi, vwma	They test whether volume supports the breakout.
Exhaustion / stretch	td_9, z_score	Both flag a late-stage rally and give multi-timeframe context.

The snapshot supplied the exact values for close_10_ema, close_50_sma, close_200_sma, rsi, the Bollinger bands, macd/macds/macdh and atr. I called adx, supertrend, td_9, z_score, obv, mfi and vwma separately. Nothing in the separate calls conflicts with the verified snapshot.

2. Price action¶

Long-run advance: AMD closed at 210.21 on 2026-04-01 and at 615.73 on 2026-10-01, which is about 2.9x (+193%) in six months.
Summer range: After a first push to 542.52 on 06-03, price spent June through August mostly between about 430 and 580. Closes peaked at 580.91 on 06-30 and bottomed at 429.56 on 07-29. In late July it fell from 552.33 (07-22) to 429.56 (07-29).
September low and rally: The low close of the recent leg was 456.16 on 09-03. From there price rose to 615.73, about +35% in four weeks.
Breakout: On 09-21, AMD gapped up from a 559.82 close to a 583.88 open, with a low of 582.27. It closed at 615.52 on 44.5M shares, the heaviest volume in the last two months of data. That cleared the prior closing high of 580.91 from 06-30.
Peak: The closing high was 630.63 on 09-25, and the intraday high of 639.00 on the same day is the highest in the window pulled.
Last four sessions: Closes of 607.87, 607.57, 611.76 and 615.73 form a tight pullback and base just below the high. Volume dried up to about 16.5–22.1M shares. That is orderly digestion, not heavy selling.
Gap: The 09-21 gap (09-18 close of 559.82, 09-21 low of 582.27) is still open. It is a reference zone, and I can't claim it acts as support.

3. Trend: strongly bullish on every timeframe, but price is far above its long-term averages¶

close_10_ema 599.43. Price is about 2.7% above it. The recent pullback held above this short-term average.
close_50_sma 511.65. Price is about 20% above it.
close_200_sma 372.59. Price is about 65% above it. The 50 SMA is well above the 200 SMA, so the long-term structure is bullish. The gap between price and the 200 SMA also shows how extended the move is.
vwma 580.21. It is below price and has risen steadily from about 470 on 09-04, so volume-weighted trading is confirming the higher prices.
SuperTrend:

Timeframe	Direction	Trailing stop	Close above stop
Weekly (primary)	Up	436.06	+41.20%
Monthly	Up	380.10	+61.99%
Daily	Up	558.12	+10.32%

All three agree, so there is no timeframe conflict. The daily stop at 558.12 sits just under the 09-18 close of 559.82, near the bottom of the breakout gap. The weekly and monthly stops are so far away that they work as regime markers, not practical stops.

4. Trend strength: ADX is cooling¶

ADX was 9.97 on 09-01 and stayed below 20 until 09-17, which means a range. It then jumped to a peak of 43.11 on 09-25 on the breakout. It has since fallen to 38.28, 34.83, 31.37 and 29.41 (10-01).

It is still above the 25 trend threshold, so the trend remains tradable.
The decline shows the directional burst has stalled into sideways digestion. This is consistent with the tight 607–616 closing range.
If ADX drops below 25 while price chops, trend-following entries become less reliable. A renewed rise with a new high would show trend re-acceleration.
I did not pull pdi/mdi, so I can't report directional dominance from them. The price path and SuperTrend indicate bulls are in control.

5. Momentum: constructive, not extreme¶

RSI 66.96. It is firm but under the 70 overbought line. There is room before it hits a conventional extreme, but strong trends can keep RSI elevated.
MACD 34.87, signal 30.07, histogram +4.81. The MACD line is above the signal line and well above zero. That is a bullish configuration. I only have the latest values, so I can't say whether the histogram is expanding or shrinking. Check that on the next bar.

6. Volatility: wide bands, large daily ranges¶

Bollinger Bands: The middle is 557.60, the upper 676.64 and the lower 438.56. Price is between the middle and the upper band, so it is not pushing the upper band. The bands are about 238 points wide after the sharp rally.
ATR 23.78. That is about 3.9% of price per day, a high-volatility name. A 1-ATR move is roughly 24 points. Stops tighter than about 1.5–2 ATR (about 36–48 points) risk being triggered by normal noise.
Reference levels for risk planning:
The 10 EMA at 599.43 is about 16 points (2.6%) below the close.
The 09-28 low of 596.07 is the low of the current pullback.
The daily SuperTrend stop at 558.12 is about 57.6 points below the close, roughly 2.4 ATR.

7. Volume confirmation: positive¶

OBV rose from 2.324B on 09-01 to 2.540B on 10-01. It reached a high of 2.545B on 09-25 and is slightly below that now. Price is also slightly below its 09-25 high, so there is no divergence between the two.
MFI reads 0.759 in the tool output. The tool reports it on a 0–1 scale, not the 0–100 scale described in the indicator's definition. Read on the 0–100 scale, that is about 76. This is a unit discrepancy in the tool, so I'm flagging it and not reconciling it. Read as 76, it is elevated but below the 80 overbought line. It peaked at about 0.84 on 09-24 and 09-25, and has eased since, while price held.
Breakout volume: The 44.5M-share day on 09-21 backs the breakout. Volume since has been light, which is typical of a consolidation. A resumption higher would ideally come with volume expanding again.

8. Exhaustion and stretch: the main caution¶

Z-score:

Timeframe	Reading	Interpretation
Weekly (primary)	+2.14	Statistically stretched
Monthly	+1.78	Elevated, not yet extreme
Daily	+0.98	Near the mean

The weekly reading is the one that matters, and it points to an overbought stretch. In strong trends that can persist, and SuperTrend and the moving averages confirm this is a strong trend. - TD Sequential:

Timeframe	Count	Interpretation
Weekly (primary)	-4	Sell setup 4 of 9
Monthly	-7	Sell setup 7 of 9, getting close to a completed 9
Daily	+4	Buy setup 4 of 9, from the last few lower-than-four-days-ago closes

The weekly and monthly sell setups say the advance is maturing. No completed 9 is in place, so there is no reversal signal yet. The daily buy setup of 4 just reflects the minor pullback from 630.63. Weekly outranks daily, so the higher-timeframe sell setups carry more weight.

9. Overall read and what to watch¶

Summary: The trend is strong and confirmed by volume, but the rally is late-stage and stretched on higher timeframes. Price is digesting gains in a tight range just under the high. The balance of evidence favors continuation while price holds the short-term averages, with elevated pullback risk because of the stretch and ADX cooling.

Bullish factors - All three SuperTrend timeframes are up. - The close is above the 10 EMA, 50 SMA, 200 SMA and VWMA. - MACD is above its signal line, and RSI of 66.96 is not yet overbought. - OBV is near its high, and the breakout came on heavy volume.

Cautionary factors - The weekly z-score is +2.14, and the monthly TD count is -7 of 9. - Price is about 20% above the 50 SMA and about 65% above the 200 SMA. - ADX is down from 43.11 to 29.41. - MFI is about 76 on a 0–100 scale, close to overbought. - Volume is light during the consolidation.

Levels and triggers, taken from tool output (confirmation is not implied) - Upside: A close above 630.63 (09-25 close) or the 639.00 intraday high would extend the breakout. Look for volume expanding and ADX turning back up. - First downside reference: 599.43 (10 EMA) and 596.07 (09-28 low). A close below both would mean the consolidation is failing. - Deeper downside references: 580.21 (VWMA), 557.60 (Bollinger middle) and 558.12 (daily SuperTrend stop). These cluster in the 557–580 area, near the 09-18 close of 559.82 and the open gap. - Further out: 511.65 (50 SMA). - Exhaustion alerts: A completed weekly or monthly TD 9, RSI above 70 combined with falling OBV, or a weekly z-score well above +2.14 with a failed new high.

I haven't tested any of these levels against past bounces, so treat them as reference points, not proven support or resistance.

Notes on data - The date used is 2026-10-01, which is the latest bar and the "now" given in the instructions. - The MFI scale issue above is the only discrepancy I found. - I did not pull pdi/mdi, stochastics, or fundamentals and news, so this report is price and indicator-based only.

10. Summary table¶

Category	Indicator	Value (as of 2026-10-01)	Reading
Price	Close / Volume	615.73 / 17.08M	Just under the 630.63 closing high of 09-25
Short-term trend	close_10_ema	599.43	Price about 2.7% above; pullback held above it
Medium-term trend	close_50_sma	511.65	Price about 20% above; bullish but extended
Long-term trend	close_200_sma	372.59	Price about 65% above; bullish structure
Volume trend	vwma	580.21	Below price and rising; confirms the uptrend
Trend direction	SuperTrend	Weekly up, stop 436.06; monthly up, stop 380.10; daily up, stop 558.12	All three up; no timeframe conflict
Trend strength	adx	29.41 (peak 43.11 on 09-25)	Above 25 but fading
Momentum	rsi	66.96	Firm, below 70
Momentum	macd / macds / macdh	34.87 / 30.07 / +4.81	Bullish; MACD above signal
Volatility	boll / boll_ub / boll_lb	557.60 / 676.64 / 438.56	Price between the middle and upper band; bands wide
Volatility	atr	23.78 (about 3.9% of price)	High; stops under about 1.5–2 ATR risk noise
Volume flow	obv	2.540B (high 2.545B on 09-25)	Rising; confirms price, no divergence
Volume flow	mfi	0.759 (tool scale 0–1; about 76 on 0–100)	Elevated, below 80; scale discrepancy flagged
Stretch	z_score	Weekly +2.14, monthly +1.78, daily +0.98	Weekly stretched; daily near the mean
Exhaustion	td_9	Weekly -4, monthly -7, daily +4	Higher timeframes maturing; no completed 9
Overall			Strong, volume-confirmed uptrend, consolidating under the high; weekly and monthly stretch plus fading ADX raise pullback risk

Sentiment Analyst¶

Overall Sentiment: Neutral (Score: 5.0/10) Confidence: Low

Data availability: no usable sentiment data for AMD (Advanced Micro Devices, Inc.) for 2026-09-24 to 2026-10-01. This report is a placeholder-level read, NOT an assessment of actual market sentiment.

1. Source-by-source breakdown - Yahoo Finance news: The source returned an "unavailable" placeholder. It only serves recent items, so this is a retrieval limitation and not evidence that there was no news about AMD. There are 0 headlines to analyze. - StockTwits: The source returned an "unavailable" placeholder for the same reason. There are 0 messages, so I can't compute a Bullish/Bearish ratio, and I can't assess retail positioning or over-extension risk. - Reddit (r/wallstreetbets, r/stocks, r/investing): Skipped because the sentiment_include_reddit config is disabled. There are 0 posts. This is a configuration choice and not a sign that the subreddits were quiet.

2. Cross-source divergences and alignments None can be assessed. With no data from any of the three sources, I can't compare institutional framing with retail sentiment.

3. Dominant narrative themes None can be identified from the evidence provided. I have not inferred themes such as AI accelerators, data-center demand, competition with Nvidia, or earnings expectations from outside knowledge, because the prompt instructs me to use only the evidence provided.

4. Catalysts and risks The data surfaced no catalysts or risks. I can't confirm any upcoming earnings date, product launch, or macro event from the supplied material. The main risk to this report is that it has no data behind it.

5. Interpretation "Neutral" at 5.0 here means "no signal", not "balanced sentiment". The downstream trader should give this report essentially no weight and rely on fundamentals, technicals, and any other sentiment feed that works. If sentiment evidence is needed, re-run the collection once the news and StockTwits feeds are available and, if wanted, with Reddit enabled.

Signal	Direction	Source	Evidence
News flow	Unknown	Yahoo Finance	Unavailable placeholder; 0 headlines
Retail Bullish/Bearish ratio	Unknown	StockTwits	Unavailable placeholder; 0 messages
Community discussion	Unknown	Reddit	Skipped by config; 0 posts
Cross-source divergence	Not assessable	All	No data
Overall	No signal (Neutral by default)	All	Confidence low; all three sources empty

News Analyst¶

AMD news and macro report (week to 2026-10-01)¶

Data coverage¶

Most of my sources returned nothing usable, so this report is thin. I have not filled the gaps with guesses.

Source	Status
AMD company news (two date ranges)	Unavailable. The Yahoo Finance feed said it only serves recent items. It also said this is not evidence that there was no AMD news.
FRED macro series (fed funds, 10-year yield, CPI, unemployment, VIX)	Unavailable. The FRED API key is not set, so I have no verified figures.
Prediction markets (Fed cuts, recession)	Withheld for this date. Polymarket only serves live odds, which would leak later information into a 2026-10-01 analysis.
Global news	Worked, but returned only headlines. Much of it is mining and commodity press releases that don't matter for AMD.

I have no AMD-specific catalysts for the week, such as product launches, customer deals, analyst actions, export rules or earnings dates. I also have no price data. The AMD view below is inferred from sector and macro headlines.

What the headlines show¶

Each item below is a headline only. I couldn't open the articles, so I have no figures or detail behind them.

1. Equities and chips - Yahoo Finance's 10/1 market wrap reads: "Dow, S&P 500, Nasdaq stage comeback as Treasury yields fall, chip stocks gain." That suggests the major indexes had sold off earlier in the week, then rebounded on 10/1 with semiconductors helping. - Barron's ran a "Micron, Accenture, Google, IBM, Fair Isaac, Synopsys… stocks that explain today's market" piece. Micron is a read-through for AI and memory demand, which matters for AMD's Instinct GPU line. I don't have Micron's actual results or guidance.

2. AI demand sentiment - Accenture's stock rose about 20–23%, its best day ever according to Barron's. Headlines cite record bookings and say they "dispel AI demand fears." IBM rose about 5% on a strong 2027 outlook, and Infosys rose about 8%. - Taken together, the market is treating AI as a demand driver for enterprise tech, not a threat to it. That is mildly supportive for AI-linked hardware names such as AMD. - IT-services stocks also rallied broadly (EPAM, DXC, EXL, Grid Dynamics, Concentrix, TaskUs). That is a sign of risk appetite in tech.

3. Rates and the Fed - A Yahoo Finance headline reads "Chorus of Fed officials warn inflation is still too high, signaling more work to do on interest rates." That points to a hawkish bias, not an easing path. - Another headline reads "10-Year Treasury yield touches highest level since 2002." I couldn't confirm the date or level, and the FRED check failed. Treat this as a possible rate-pressure risk, not a confirmed fact. The 10/1 wrap does say yields fell that day. - A silver headline mentions "the latest PCE report" on 10/1, so PCE inflation data was apparently released. I have no figures or reaction.

4. Risk warnings - MarketWatch: bond investor Jeffrey Gundlach warns the stock market is "a hollow tree that could be about to snap." This suggests narrow leadership and fragility. AMD is a high-beta, high-multiple stock that would be exposed to a sharp drawdown.

Implications for AMD (inferred)¶

Supportive: A chip-led rebound, AI-demand relief from Accenture and IBM, and falling yields on 10/1 are all tailwinds for semiconductors.
Risks: Hawkish Fed commentary, possibly very high long-term yields, and warnings of narrow, fragile market breadth. Higher discount rates hit long-duration growth names like AMD hardest.
Unknown: I don't know AMD's price action, recent news flow, the Fed's current rate level, or inflation and labor data. These need to come from other sources before sizing a trade.

Suggested follow-ups for the next analyst¶

Get AMD price, volume, and technicals through 10/1.
Check AMD-specific items: Instinct and MI-series roadmap, hyperscaler or OpenAI-type deals, Nvidia competition, China export-control news, and the Q3 earnings date (likely late October or early November).
Get the actual PCE print, the 10-year yield level, and the Fed funds level from another source.
Read the 10/1 market wrap and the Micron article for details on chip-sector moves.

Summary table¶

Area	Finding	Source quality	Read-through for AMD
AMD company news	Not retrievable	Tool unavailable	Unknown, so no catalyst view
Equity markets 10/1	Indexes rebounded, yields fell, chips gained	Headline only	Short-term positive
AI demand	Accenture up about 20–23% on record bookings, IBM up about 5%, IT services rallied	Headlines	Mildly positive for AI sentiment
Micron and memory	Named among the day's market movers	Headline only, no details	Possible AI-hardware read-through, unverified
Fed and inflation	Fed officials say inflation is still too high; PCE released 10/1	Headlines, no figures	Hawkish, a valuation headwind
Long yields	Headline says 10-year at its highest since 2002 (date and level unconfirmed); yields fell on 10/1	Headlines, conflicting timing	Rate-pressure risk
Market fragility	Gundlach warns of a "hollow" market	Opinion headline	Drawdown risk for high-beta tech
Macro data (FRED)	Not retrievable	API key missing	No verified numbers
Prediction markets	Withheld for this date	Tool restriction	No probability data

Fundamentals Analyst¶

AMD (Advanced Micro Devices, Inc.) – Fundamental Report as of 2026-10-01¶

0. Data scope and caveats¶

Profile data is unavailable. The get_fundamentals tool withheld market cap, valuation multiples, the 52-week range and the TTM snapshot. The vendor only serves present-day values, so using them would leak post-decision information. This report has no vendor-sourced P/E, EV/EBITDA, or market-cap figures.
Latest reported quarter is Q2 2026 (period ended 2026-06-30). Q3 2026 ended on 2026-09-30 and has not been reported. The statements don't include filing dates, so I treat Q2 as the latest known data.
Insider prices are the only price evidence. Form 4 sale prices were about $498–516 in September 2026. I use them only as rough context, not as a quote.
Discontinued operations. Net income includes small discontinued-operations items (–$8M in Q2 2026). This is likely related to the ZT Systems manufacturing divestiture, since "assets held for sale" appeared on the balance sheet in mid-to-late 2025. I haven't confirmed that.

1. Income statement: strong acceleration¶

$M	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Revenue	7,685	9,246	10,270	10,253	11,536
Gross profit	3,059	4,780	5,577	5,416	6,203
Gross margin	39.8%	51.7%	54.3%	52.8%	53.8%
R&D	1,894	2,139	2,330	2,397	2,528
SG&A	991	1,069	1,198	1,253	1,401
Operating income	–134	1,270	1,752	1,476	1,990
Operating margin	–1.7%	13.7%	17.1%	14.4%	17.3%
EBITDA	721	2,106	2,861	2,398	3,353
Net income	872	1,243	1,511	1,383	2,297
Diluted EPS	0.54	0.75	0.92	0.84	1.38

Key observations - Growth. Q2'26 revenue rose about 50% YoY and about 12.5% QoQ. Trailing-four-quarter revenue is about $41.3B, and the last four quarters are the four highest in this table. - Gross margin. Q2'25 (39.8%) was depressed, probably by the export-control-related inventory charge on MI308 that AMD took in 2025. That cause is from my background knowledge, not from the tool output. The ~52–54% range since then looks like the normalized level. Q2'26 recovered to 53.8% after dipping to 52.8% in Q1. - Operating leverage is real but partial. Revenue grew 50% YoY and operating expenses grew about 32% ($3.19B to $4.21B). R&D is 21.9% of revenue and SG&A is 12.1%. SG&A rose 12% QoQ, which is worth watching. - Earnings quality. - Q2'26 net income of $2.30B was helped by $598M of "other income". The cash flow statement shows a $483M investment gain, likely mark-to-market on investments. - The tax rate was only 9.8% (Q1: 14.8%). - Operating income of $1.99B is the cleaner earnings measure. EPS of $1.38 is flattered; I estimate $1.0–1.1 on a normalized basis (a rough calculation using a ~15–20% tax rate, not a reported figure). - TTM figures. Diluted EPS is about $3.89 (0.75+0.92+0.84+1.38) and net income is about $6.43B. At roughly $500 per share, as the September insider prints suggest, that implies a trailing P/E above 125x. This is illustrative only. The valuation therefore bakes in a lot of forward growth, so the stock is sensitive to any guidance miss. - Non-cash drag. Intangible amortization from the Xilinx acquisition is declining ($308M to $284M per quarter) but still total about $544M per quarter in cash-flow terms.

2. Balance sheet: solid and improving¶

$M	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Cash + ST investments	5,867	7,243	10,552	12,347	13,111
Total debt (incl. leases)	3,886	3,870	3,847	3,871	4,276
Inventory	6,677	7,313	7,920	8,045	8,468
Accounts receivable	5,115	6,201	6,315	6,035	7,281
Accounts payable	3,080	3,483	2,929	2,997	5,359
Total assets	74,820	76,891	76,926	79,642	84,464
Equity	59,665	60,790	62,999	64,462	67,224

Liquidity.
Net cash is about $8.8B ($13.1B cash and investments less $4.3B total debt).
The current ratio is 2.6x ($31.5B of current assets against $12.1B of current liabilities).
Working capital is $19.4B.
Debt.
Financial debt is about $3.2B ($2.35B long-term plus $875M current).
Capital leases jumped to $1.05B from $647M, consistent with the capacity and data-center buildout.
Debt-to-equity is low at about 0.06x. There was no new debt issuance in the period.
Goodwill and intangibles are $41.1B, about 49% of total assets. Tangible book value is $26.1B. Impairment risk is low while earnings are growing, but this would matter in a downturn.
Working capital build.
Inventory is $8.5B, about 144 days of cost of revenue, and has risen from $6.7B in a year. This is a risk if demand softens or product transitions are mishandled. It also supports the supply needed for the ramp.
Receivables rose 21% QoQ to $7.3B. DSO is about 57 days, against about 54 days in Q1. Revenue was back-end loaded or customer payment terms stretched.
Payables jumped by $2.4B to $5.4B and offset much of that. This is a timing benefit that could reverse.
Share count. Shares outstanding are 1.632B. Treasury stock was retired in Q2, which is a presentation change and not a new buyback.

3. Cash flow: healthy, but capex is ramping¶

$M	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Operating cash flow	2,011	2,159	2,600	2,955	2,366
Capex	–282	–258	–222	–389	–808
Free cash flow	1,729	1,901	2,378	2,566	1,558
Buybacks	–524	–460	–160	–355	–207
Stock-based compensation	369	419	486	487	503

TTM free cash flow is about $8.4B, roughly 20% of revenue and about 130% of TTM net income.
Q2'26 free cash flow fell 39% QoQ.
Capex doubled QoQ to $808M and is nearly 3x the level a year ago.
Working capital was a –$730M drag, mainly from a receivables build (–$1.25B) and an inventory build (–$423M), partly offset by payables (+$2.27B).
Operating cash flow of $2.37B was also below net income plus D&A and stock-based compensation, once you strip out the $483M non-cash investment gain.
Capital returns are modest.
Buybacks over the last four quarters total about $1.19B, against about $1.9B of stock-based compensation. Repurchases don't offset dilution.
Diluted shares rose from 1,630M to 1,659M (+1.8% YoY).
AMD pays no dividend.
Uses of cash. Most surplus cash is going into short-term investments (net purchases of $1.7B in Q2) and growing capex.

4. Insider activity (Form 4, through 2026-09-15)¶

Selling dominates, with no open-market insider buying since early 2025. The last purchases were by Philip Guido: 4,645 shares at $107.56 in Feb 2025 and 8,800 shares at $113.56 in May 2025.
CEO Lisa Su
She sold 95,000 shares (~$48.1M, $503–516) on 2026-09-10 and gifted 35,000 shares.
Other sales: 15,000 shares (~$7.2M) on 2026-08-18, 125,000 (~$57.6M) on 2026-06-10, 125,000 (~$55.7M) on 2026-05-13, 85,000 on 2026-03-12, and 125,000 on 2026-02-11 and again on 2025-12-11.
The regular cadence, about every 1–3 months, suggests pre-arranged plans (10b5-1). The filings don't confirm this.
Others.
EVP Forrest Norrod has sold roughly monthly after option exercises; the latest were 17,261 shares (~$8.7M) on 2026-09-15 and the same size on 2026-08-24.
CTO Mark Papermaster has sold regularly on a monthly option-exercise schedule. The latest were 28,811 shares (~$13.6M) on 2026-08-20 and 7,369 shares on 2026-08-14.
CFO Jean Hu sold 15,000 shares (~$7.1M) on 2026-08-25.
Paul Grasby sold 15,000 shares (~$7.7M at $515) on 2026-08-17.
General Counsel Ava Hahn sold small lots.
Director Nora Denzel sold 10,447 shares (~$5.5M at $522) on 2026-06-02.
Size. Disclosed sales since 1 August 2026 total roughly $106M, with Su accounting for about $55M. Many August entries have no value. They are likely vesting or tax-withholding events, but the tool doesn't label them.
Interpretation. The selling coincides with a very large run-up in the stock. Insider trade prices went from about $198–220 in Feb–Mar 2026, to $350 in late April, to $430–460 in May, and a peak of about $556 in July. It then traded at $450–515 in Aug–Sept. The selling looks like routine, plan-driven profit-taking and isn't a clear bearish signal. There are still no insider buys to support the valuation.

5. Trading implications¶

Positives 1. Revenue grew ~50% YoY, with sequential growth and a gross margin stable at 52–54%. 2. Operating margin is at a cycle high of 17%, and operating income is growing faster than revenue. 3. The balance sheet is strong: $8.8B net cash and little financial debt. 4. TTM free cash flow of ~$8.4B and rising capex signal capacity investment for growth.

Risks and watch items 1. Valuation. Using the insider-print price, the trailing P/E is above 125x. Any shortfall against expectations could cause a sharp reaction. The stock has more than doubled since March. Check live multiples and consensus data elsewhere. 2. Earnings quality. Q2 EPS benefited from a ~$483M investment gain and a 9.8% tax rate. 3. Working capital. Inventory and receivables are growing, and payables flattered Q2 operating cash flow. A reversal could weigh on Q3 free cash flow. 4. Capex step-up. Capex of $808M, up 3x YoY, and rising leases will pressure free cash flow before revenue benefits. 5. Dilution. Stock-based compensation of about $2B a year exceeds buybacks, and the share count is creeping up. 6. Goodwill. $41B of goodwill and intangibles leaves tangible equity at about 39% of total equity. 7. Event risk. Q3 results are due, likely in early November. I didn't verify the date. Guidance, MI-series GPU ramp commentary, and export-control issues are the key swing factors.

6. Summary table¶

Category	Key point	Latest data (Q2'26 unless noted)	Signal
Revenue	~50% YoY growth, 12.5% QoQ	$11.54B (TTM ~$41.3B)	Positive
Gross margin	Stable at the post-charge level	53.8% (Q1: 52.8%; Q2'25: 39.8%)	Positive
Operating income	Margin at a cycle high	$1.99B (17.3%)	Positive
Net income / EPS	Boosted by investment gain and low tax	$2.30B / $1.38 (TTM EPS ~$3.89)	Mixed (low quality)
Opex	Opex +32% YoY, below revenue growth	R&D 21.9%, SG&A 12.1% of revenue	Neutral/positive
Liquidity	Net cash ~$8.8B, current ratio 2.6x	Cash and investments $13.1B	Positive
Debt	Low leverage, leases rising	Total debt $4.28B	Positive
Goodwill and intangibles	49% of assets	$41.1B	Risk (impairment)
Inventory	Up 27% YoY, ~144 days	$8.47B	Watch
Receivables	+21% QoQ, DSO ~57 days	$7.28B	Watch
Free cash flow	Down 39% QoQ on capex and working capital	$1.56B (TTM ~$8.4B)	Mixed
Capex	~3x YoY	$808M	Watch
Buybacks vs. stock comp	Buybacks don't offset dilution	$207M vs. $503M	Negative
Insiders	Heavy planned selling, no buys since May 2025	~$106M sold since Aug 1; Su ~$55M	Mild negative / neutral
Valuation	Vendor data withheld	Trailing P/E above ~125x at ~$500 (illustrative)	Rich, verify elsewhere
Next catalyst	Q3 2026 results not yet reported	Likely early Nov (unverified)	Event risk

II. Research Team Decision¶

Bull Researcher¶

Bull Analyst: # Bull Case for AMD at $615.73

I'll start with what AMD has done, then take on the objections I expect from the bear.

1. The business is inflecting, not just the stock¶

Revenue - Q2'26 revenue was $11.54B, up about 50% YoY and 12.5% QoQ. - Trailing four quarters total about $41.3B. - Revenue has risen in four of the last five quarters, and Q1'26 was essentially flat on Q4'25.

Profitability - Operating income went from –$134M in Q2'25 to +$1.99B in Q2'26. - Operating margin is 17.3%, a cycle high. - Gross margin has held at 52–54% for four straight quarters. That matters because it shows the 39.8% print a year ago was a one-off hit, not the new normal. - Opex grew about 32% against 50% revenue growth, so operating leverage is already showing.

Cash and balance sheet - TTM free cash flow is about $8.4B, roughly 20% of revenue. - Cash and investments are $13.1B against $4.3B of total debt, so net cash is about $8.8B. - The current ratio is 2.6x and debt-to-equity is about 0.06x. - AMD can fund a capacity buildout without a financing risk.

This is a company converting a demand surge into operating profit and cash, on a balance sheet that can absorb a mistake.

2. The market is confirming it¶

Breakout on conviction. On 09-21 AMD gapped up and closed at 615.52 on 44.5M shares, the heaviest volume in two months. It cleared the June closing high of 580.91.
Orderly digestion. Since the 630.63 closing high on 09-25, the stock has closed in a tight 607–616 band on 16–22M shares. That is a pause, not distribution. The pullback held above the 10 EMA (599.43).
Every trend marker agrees. Weekly, monthly and daily SuperTrend are all up. Price is above the 10 EMA, 50 SMA, 200 SMA and VWMA. MACD is above its signal line.
No divergence. OBV is at 2.540B against a high of 2.545B, so volume flow matches price.
Room on momentum. RSI is 66.96, under 70. In strong trends it can stay elevated for a long time.
Macro on 10/1. Headlines describe a market rebound with falling yields and chips leading. Accenture's best day ever on record bookings and IBM's strong outlook suggest AI demand fears are easing.

3. Answering the bear¶

"It's up 2.9x in six months and stretched." Yes, the weekly z-score is +2.14, the monthly TD count is –7 and price is 65% above the 200 SMA. But those are statements about price, and price rose because earnings power changed. Operating income swung by more than $2B a year. Stretch readings can persist for a long time while earnings revisions are positive. No completed TD 9 is in place, so there is no exhaustion signal yet. The daily z-score is just +0.98, so the short-term chart is near its mean after four sessions of consolidation.

"ADX is falling from 43 to 29." ADX measures trend strength, not direction. It spiked on a gap-up breakout and is cooling because price is going sideways in a tight range. It is still above 25. A falling ADX during a flat base is what consolidation looks like.

"Valuation is rich. Trailing P/E is over 125x." This is the bear's strongest point, so I won't dodge it. At 615.73 on TTM EPS of about $3.89, the trailing multiple is roughly 150x or more, and the market cap is about $1T on 1.632B shares. I'm not going to claim that's cheap on trailing numbers. But trailing multiples on a company that swung from an operating loss to a 17% operating margin in four quarters describe the past, not the slope. - Revenue is growing 50% YoY. - Operating income grew faster than revenue. - Gross margin is steady, so incremental revenue is dropping through at high margin.

The thesis is that the earnings base is compounding fast enough that today's multiple compresses through growth rather than through price. The trade-off is that the stock needs the growth to continue, and I own that.

"Earnings quality is poor. Q2 EPS was flattered." The fundamentals report is right that Q2 net income of $2.30B included $598M of other income and a 9.8% tax rate. But I'm not leaning on EPS. Operating income of $1.99B is the clean number, and it is up from $1.48B in Q1. Even the report's normalized EPS estimate of $1.0–1.1 is roughly double Q2'25's reported $0.54.

"Free cash flow fell 39% QoQ." That was a capex and working-capital story, not an earnings problem. Capex doubled to $808M as AMD builds capacity, and receivables grew with a 50% revenue increase. TTM FCF is still $8.4B, about 130% of net income. Spending three times last year's capex while still generating that cash is what a company does when it sees demand ahead.

"Inventory and receivables are building." Inventory of $8.5B and DSO of about 57 days (54 in Q1) deserve monitoring. But a company growing revenue 50% and ramping new products needs supply on hand. With $13.1B of liquidity, working capital is a timing question, not a solvency one.

"Insiders are selling. Lisa Su sold about $48M on 09-10." The cadence is regular, with CEO sales every one to three months, and the fundamentals report itself calls it plan-driven profit-taking. That pattern fits pre-arranged 10b5-1 sales, though the filings don't confirm it. Executives with large option and equity grants after a roughly 3x run will sell for diversification. There are also no open-market buys since 2025, but there were none when the stock was at $200 either. I wouldn't read a signal into that.

"Dilution: stock comp exceeds buybacks." Share count is up only about 1.8% YoY, against 50% revenue growth. That is a small cost.

"Goodwill is 49% of assets." That is a legacy of the Xilinx deal. Impairment risk is low while earnings are growing, and the drag from amortization is declining ($308M to $284M per quarter).

4. The risks I accept¶

Q3 results are expected in late October or early November (unverified). With the stock this extended, guidance carries heavy weight.
Fed commentary is hawkish, and a headline says the 10-year touched its highest since 2002. I couldn't verify the level or date, and yields fell on 10/1.
Gundlach's warning about a "hollow" market is a reminder that a high-beta name can fall hard.
Sentiment and AMD-specific news data came back empty, so I'm not claiming any retail or news support.

5. How I'd frame the trade¶

The evidence points to a real fundamental inflection, a volume-confirmed breakout and orderly consolidation. The risks are valuation and extension, which is where a position-sizing discipline comes in: - Upside trigger: a close above 630.63 (or the 639.00 high) on expanding volume. - First warning: a close below 599.43 and 596.07. - Deeper reference zone: 557–580, near the VWMA, Bollinger midline and daily SuperTrend (558.12). - Stops: with ATR at 23.78 (about 3.9% a day), stops tighter than 1.5–2 ATR risk being hit by noise.

My challenge to the bear¶

You'll point at the multiple and the chart. My question is what your forward earnings path is. If operating income keeps compounding at anything like the last four quarters' pace, which part of the thesis breaks, and what evidence in the data we have says it will? What I see is accelerating revenue, expanding margins, a net-cash balance sheet and a tape that hasn't broken. I'd like to hear your counter. Bull Analyst: # Bull Rebuttal: Where I Concede, and Where the Bear's Math Breaks

I'll start with the concessions, because they narrow the debate to the real disagreement.

Conceded: - Multiple expansion. The price rose 193% while quarterly operating income rose 14% from Q4'25 to Q2'26. On an annualized-operating-income basis the multiple went from roughly 49x to 126x. I can't show you the consensus revisions behind that, and the packet has no guidance, segment mix or customer data. That is a hole in my case. - Double-counting the base. You're right that I used the Q2'25 base both ways. I'm dropping the YoY operating-income swing and the "normalized EPS is double" line. - Macro. One day of unopened headlines isn't evidence. Accenture and IBM are services names, not GPU demand. I'm withdrawing it as support. - Duration. A 24x-sales stock is hurt by higher discount rates. The "highest since 2002" yield headline is unverified, and so is the 10/1 yield drop that I leaned on. Neither of us can lean on rates.

1. Incremental margin depends on your starting quarter¶

You measured from Q4'25 and got 19%. Here are three starting points:

From → Q2'26	Δ Revenue	Δ Op income	Incremental margin
Q4'25	+$1.27B	+$238M	19%
Q3'25	+$2.29B	+$720M	31%
Q1'26	+$1.28B	+$514M	40%

Q3'25 is the cleaner base. It is the first quarter after the gross-margin charge, so it avoids the distorted quarter. From there incremental margin is 31%, nearly double the 17.3% average. I'll concede that much of it is gross-margin recovery (51.7% to 53.8%), not opex leverage. R&D plus SG&A rose 22.5% against 24.8% revenue growth, so that is thin.

2. "What you have to believe" is really one question: operating leverage¶

Your $20.50 EPS target needs 75% revenue CAGR only if net margin stays at 15%. Here is my back-of-envelope version, which is mine and not from the packet: - Revenue grows about 36% a year for four years, to roughly $140B. That is a deceleration from the 50% AMD just delivered. - R&D plus SG&A grows at two-thirds of the revenue rate, which is what happened YoY (32% opex against 50% revenue). - Gross margin stays around 54%. Operating margin reaches about 30%, and EPS is about $20.

So the requirement drops from 75% growth to the mid-30s, but only if opex discipline holds. Over the last three quarters opex grew at about 90% of the revenue rate, not 64%. At that ratio EPS is about $15 and the stock needs a 40x multiple to hold. That is the crux. I'm not claiming a margin of safety at $615. I'm claiming the outcome hinges on opex growth relative to revenue, and Q3 will show which ratio is real.

I'd also push back on "even if earnings double, you pay 75x." Doubling isn't a long-dated outcome here. Annualized Q2 operating income is already $8.0B against $6.5B TTM.

3. Cash quality: you isolated one line¶

Stripping the $2.27B payables increase leaves $96M of operating cash flow. That removes the helpful working-capital line and keeps the harmful ones (receivables –$1.25B, inventory –$423M). Total working capital was a –$730M drag. Remove all of it and Q2 operating cash flow is about $3.1B, not $100M.

You're right that payables can reverse, and that receivables (+21% against 12.5% revenue growth, DSO 54 to 57) need to normalize. A Q3 collections reversal would offset a payables unwind. That's why I'll adopt your DSO test below.

I also concede the 0.8% FCF yield. It isn't a yield story. About $808M of Q2 capex is growth spending.

4. Dilution¶

GAAP operating income already includes the roughly $1.9B of stock comp, so the 17.3% margin is after that cost. The $18B figure takes 1.8% of today's market cap, but the cost to holders is the grant value, which is in the P&L. Part of the diluted-count creep is also mechanical when a stock triples (treasury method). I can't verify that split from the packet. With revenue up 50% against 1.8% share growth, per-share revenue growth is still about 47%.

5. The tape¶

ADX under 20 until 09-17 is what a base looks like. A flat range followed by a volume spike is the signature of a breakout. It doesn't mean the trend is two weeks old. Weekly and monthly SuperTrend are up, and the stock is up 193% in six months.
The 6% above 580.91 is the point. The stock is near the pivot, so invalidation is close. A close back below 580.91 (about –5.7%) means the breakout failed.
Your –9.4% SuperTrend stop isn't my invalidation level, and the upper Bollinger band (+9.9%) isn't a ceiling in a trend. A base-breakout measured move (the 430–580 range height added to the breakout) points toward about 730, or +18%. That is a heuristic, not a forecast.
The caveat is mine. 580.91 is about 1.5 ATR below the price, at the edge of noise. Use closes, and treat 558 (daily SuperTrend, the bottom of the gap) as the second line.
The –22% week (552 to 429.56) is real. It was also fully recovered, to new highs, in about two months. That is a sizing argument, not a reason to avoid the stock.

6. Your four tests¶

I'll accept the first three as the joint thesis test: 1. Q3 operating margin above 18–19%. 2. DSO normalizing. 3. Guidance implying sequential growth above recent quarters.

Your fourth, a reset to $510, is a price preference, not a thesis test. If the stock gets there without thesis damage, I'd add.

Where that leaves us¶

You've shown the stock offers no valuation cushion, and I agree. My claim is narrower. The data show a business whose margins and cash generation are moving the right way, with a breakout whose failure point is clearly defined. The unresolved question is operating leverage, and the Q3 print will answer it.

Given a binary print one session after quarter-end, I'd hold at reduced size into it. I'd add on a close above 630.63 with expanding volume, and reduce on a close below 580.91.

If Q3 passes your three tests, what's left of the bear case? Bull Analyst: # Bull Final Response: We've Converged on the Action, and the Price Is What's Left

Where you're right¶

Your table is sound arithmetic. The multiples are yours and the EPS paths are mine, but the message holds. At $615 the base case is roughly zero to 7% a year (–3% to +30% over four years). The stock pays only if revenue or margins beat what I modeled. I'm not claiming a margin of safety.
Gaps beat stops. "Reduce on a close below 580.91" does nothing through an earnings gap. Against event risk, only position size works.
The $3.1B ex-working-capital cash flow is withdrawn, along with your $100M. The likeliest explanation for the unreconciled $1.3B is unitemized working-capital lines (accrued liabilities, other current assets, taxes), not a contradiction. If so, Q2 cash conversion was weaker than I presented. What survives is that Q2 operating cash flow leaned on payables, so DSO and operating cash flow ex-payables are Q3 checks.
40% incremental margin is rebound arithmetic from the Q1 trough.
Passing Q3 doesn't make the stock cheap. About 108x annualized operating income is still rich.

Where I push back¶

1. The base I dropped was dropped for a specific reason. I dropped the Q2'25 operating-income swing because the distortion sat in cost of revenue (gross margin 39.8%). R&D and SG&A aren't in cost of revenue. On R&D plus SG&A alone, Q2'25 to Q2'26 is +36% against revenue +50%, a ratio of about 0.72, not 0.91.

I'll flag the limit myself: if Q2'25 revenue was also depressed by export restrictions (my background knowledge, not in the packet), the 0.72 is flattered. The truth is probably between 0.72 and 0.91, which is why one print can't settle it.

2. The leverage arrives in steps. From the packet:

	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26
Revenue QoQ	–	+20.3%	+11.1%	–0.2%	+12.5%
R&D+SG&A QoQ	–	+11.2%	+10.0%	+3.5%	+7.6%
R&D+SG&A % of revenue	37.5%	34.7%	34.4%	35.6%	34.1%

Opex grows about 3.5–11% a quarter. The ratio falls when revenue growth beats that, as it did in Q3'25 and Q2'26, and it stalls when revenue stalls, as in Q1. So the question is whether revenue keeps growing faster than about 8% a quarter, and your 0.6-point trend is an average over that mix. I'm not claiming the ⅔ ratio is likely. It needs opex growth to slow from about 7% to about 5% a quarter, and with SG&A up 12% in Q2 that's not obviously achievable.

3. Your fourth test is "repeat Q2." At Q2's 7.6% opex growth, getting below 33% needs Q3 revenue of about $12.8B, up 11.1%. That's a real bar, since it requires a Q2-like quarter, but it's a fair one, and I accept it.

4. SBC so far argues against the pressure you describe. SBC rose 36% YoY ($369M to $503M) against revenue's 50%, and fell from 4.8% to 4.4% of revenue. Higher-priced grants vest with a lag, so your risk is real, but the evidence is on my side so far. I'd flag it if SBC rises above 5% of revenue.

5. "Priced in" cuts both ways. You say the tape shows the market expects a pass. But you also conceded that the re-rating from $210 rests on information we can't see. We can't use unseen expectations as evidence in both directions.

6. A correction to my own framing. I called Q3 "a binary print one session after quarter-end." The quarter ended 09-30, but the report is likely four to five weeks out (late October to early November, unverified). That time matters, because the tape will test 580.91 and 630.63 before the print. We can size and stage into the event instead of deciding today.

The one claim that remains¶

My claim is that the 3-quarter revenue run rate annualizes to about 34%, which is what my 36% path assumed. Holding that pace for four years is the hard part, and the packet has no backlog, guidance, segment mix or customer data to say whether it can. That's the hole in my case. The stock is a bet on execution, priced for it, with a balance sheet that can absorb a mistake.

Where we end up¶

Trigger	Action
Close above 630.63 on expanding volume	Add
Close below 580.91	Reduce
Close below 558 (daily SuperTrend, bottom of the gap)	Cut further
Pullback toward 510 (50 SMA), thesis intact	Add
Q3 passes all four tests	Move toward full size

The four tests: 1. Operating margin above 18–19%. 2. DSO back toward 54 days. 3. Guidance implying sequential growth above recent quarters. 4. R&D plus SG&A below 33% of revenue.

Sizing: because the stock fell 22% in five sessions in July and earnings gaps skip stops, the position should be small enough that a 20% gap is tolerable.

Bottom line: Both sides would reduce or hold small, add on strength or weakness at defined levels, and wait for Q3. The remaining disagreement is whether to hold a small position or none. I'd hold it, because the volume-confirmed trend and the operating trajectory are real and the downside is controlled by size. You'd rather wait for a price that pays you for the risk. I can't call that wrong, but if Q3 passes all four tests, I'd say the case for owning it gets much harder to dismiss. Bull Analyst: # Bull Close: Fix the Plan, Keep a Small Position

What I concede¶

The trigger table whipsaws as written. 630.63 to 580.91 is about 2 ATR, and the stock traded inside that range last week. Buying strength and selling weakness inside two ATRs of noise bleeds in a range. I'm dropping both the 630.63 pre-print add and the 580.91 reduce.
Sizing is not edge. It caps the loss and nothing more. The edge I can defend is modest: trend persistence and a positive operating trajectory. It is not a valuation edge.
"Full size" on a pass was too strong. A clean Q3 still leaves AMD near 108x annualized operating income. A pass should raise my confidence in the revenue path, but I should scale size to the price relative to the four-year return table, not to the tests alone.
The opex ratio has been range-bound since Q3'25 (34.7%, 34.4%, 35.6%, 34.1%). I can't claim a demonstrated downtrend in it.
My table gives roughly 0–7% a year at 30x. That is thin, and I'm not disputing it.

Where the bear's close overreaches¶

1. The opex ratio is a function of revenue growth, not a time trend. In Q1 revenue was flat (–0.2%) and the ratio rose 1.2 points. In Q2 revenue grew 12.5% and it fell 1.5 points. That is what you'd expect from opex growing 3.5–8% a quarter whatever revenue does. Extrapolating "0.6 points per three quarters" averages a flat-revenue quarter into a leverage estimate.

The real hurdle, by my arithmetic, is that opex growth has to slow from roughly 30% annualized to roughly 22% while revenue compounds at 36%. That is demanding, and SG&A's 12% QoQ jump in Q2 shows why. But it is a narrower claim than "10 points of leverage from nowhere," and Q3 tests it directly.

2. The exit multiple is an assumption, not data. The whole 25x/30x/40x spread, from –19% to +30% on the $20 path, comes from multiples neither of us can anchor. If AMD really compounded revenue at 36% for four years, it would probably still be growing well above 20% in year four. That makes 30x less generous than it looks. This is my reasoning and the packet has nothing to confirm it. But the bear's "break-even at 30x" is a result of an assumed multiple, not a finding.

3. Volatility is two-sided. A high-teens one-sigma over 24 sessions applies to the upside too, and the bear concedes missing about 18% if the measured move plays out. Volatility alone doesn't make the expected return negative.

4. "A pass only protects against a loss that was never the central risk" is too strong. At 126x annualized operating income, a Q3 that fails the margin, DSO or opex test is exactly how a 20% gap happens. The tests do bear on the central risk. They shrink the left tail, which supports sizing up. They don't make the stock cheap.

Revised plan¶

Situation	Action
Now	Hold small, sized so a 20% gap is tolerable. No price-based adds into the print.
Pullback toward ~510 with thesis intact	Add (we agree)
Daily close below 558 (SuperTrend, bottom of the gap)	Cut
Q3 passes all four tests	Add toward normal size, scaled to the then-price against the return table
Q3 fails two or more tests	Exit

The four tests remain: 1. Operating margin above 18–19%. 2. DSO back toward 54. 3. Guidance implying sequential growth above the recent run rate. 4. R&D plus SG&A below 33% of revenue.

Bottom line¶

We now agree on the tests, the sizing logic and the pullback add. What's left is whether to hold a small position or none for the roughly 24 sessions to the print.

The bear's case is stronger on valuation. Mine is stronger on trajectory: 50% growth, a net-cash balance sheet, a breakout on volume, and an operating-leverage question that Q3 answers. I can't prove a positive expected return at $615, and I won't pretend a stock at 126x annualized operating income has a margin of safety. I'm holding because trend and trajectory both point up, and small size makes being wrong survivable.

I'd also say what proves me wrong: operating margin below 17%, the opex ratio back above 35%, DSO at 57 or higher, and flat guidance. If the print shows that, the trajectory argument is gone and I exit. Bull Analyst: # Bull Final: Where We Actually Disagree

I'll concede what's earned, then argue the two things I think still favor a small position.

What I concede¶

The tape isn't evidence of why the stock moved. The 09-21 gap came on 44.5M shares with no news in our packet. Volume shows participation, not what was priced. I'm dropping "confirmed breakout" as a fundamental claim. The only thing the trend gives me is a statistical tendency toward persistence.
Your measured-move arithmetic is right. Reaching about 730 after a clean Q3 means the stock holds roughly 127x annualized operating income. That is a re-rating repeating, not growth catching up. I'll keep 730 as a chart reference only, not as a forecast.
My central case is thin. I called the ⅔ opex ratio "not obviously achievable," so my honest EPS estimate sits between your $15 and $20 rows, around $17. At 30x that is about $510 (–17%). At 35x it is about $595. Only 40x pays. The packet gives me no way to show a better multiple than that.
Q3 can't settle a four-year revenue path. It tells us about one quarter. The most useful forward information in a print is guidance and data-center commentary, and our packet has none of that.

Where I still disagree¶

1. The exits cover two different risks. You say "cut below 558" and "exit on a failed Q3" both execute after the gap. That's true of the second, but not the first. About 24 sessions of continuous trading come before the print, and this stock fell 22% in five sessions in July without an earnings release. The 558 rule covers drift, and position size covers the gap. They are two tools for two risks, and neither claims to create edge.

2. Waiting isn't free, and it isn't neutral. You say that if I wait, I get the same information and skip the gap. But you skip both tails. If gaps are fairly priced, the expected contribution of the gap is about zero, and what a holder earns before the print is the modest drift of an existing trend. What a waiter gains is a conditional distribution. That is a risk preference, the same kind of thing as sizing, and not an edge. Waiting also has a concrete cost: on a pass you buy after the gap, at a higher price and a higher multiple than the 108x we computed. Your plan says you'd "reassess at the then-price," so in practice your buy condition is a limit order near $510. With ATR near 3.9%, a roughly 17% pullback inside 24 sessions is plausible, so that order may well fill. But it may not, and then "wait" means "never."

3. The $15 row is a floor case, not my likely case. It combines revenue growth of 36%, below the 50% just delivered, with opex growing at 90% of revenue. I won't call it unlikely, since three quarters of data support it. But a four-year path that holds either revenue growth above 36% or opex below 90% of it lands higher. The table also values only earnings and ignores the cash that accumulates. Net cash is $8.8B today, and TTM FCF is $8.4B and growing. Some of that is already in EPS through interest income, so I won't claim it adds much. It shifts the table slightly my way, not enough to change the conclusion.

Where we end up¶

	Bull (me)	Bear
Today	Hold small, sized to survive a 20% gap	No new position; trim if held
Before the print	Cut on a daily close below 558	Not applicable
Pullback to ~510, thesis intact	Add	Add
Q3 passes all four tests	Add, scaled to the then-price against the return table	Reassess at the then-price
Q3 fails two or more tests	Exit	Already out of the way

The four tests are: 1. Operating margin above 18–19%. 2. DSO back toward 54. 3. Guidance implying sequential growth above recent quarters. 4. R&D plus SG&A below 33% of revenue.

Bottom line¶

I can't show you a valuation edge at $615, and my own central case returns about zero at a 30x multiple. We agree on the tests, the pullback add and the sizing logic. What's left is whether a small holding through about 24 sessions is worth it, and I'd say it is, for three reasons:

AMD has real operating momentum: 50% revenue growth and an operating margin at a cycle high of 17.3%.
It has a balance sheet that can absorb an execution mistake.
Its trend is intact.

Those are reasons to hold a small position and not reasons to add. A holder who stays small pays for being wrong in a bounded way. A waiter pays for being wrong by missing the upside. Neither plan is unreasonable, and the Q3 print will show which of us paid less.

What would prove me wrong: operating margin below 17%, R&D plus SG&A back above 35% of revenue, DSO at 57 or higher, or flat guidance. Any two of those and I'd exit.

Bear Researcher¶

Bear Analyst: # Bear Case for AMD at $615.73

You asked which part of the thesis breaks. I'm not arguing that earnings collapse. I'm arguing that the price already assumes a decade of the good outcome, and that your causal story doesn't hold up against the numbers we have.

I'll concede what's real: the growth is genuine, the balance sheet is clean, and the 09-21 breakout had volume behind it. None of that is in dispute.

1. "Price rose because earnings power changed" doesn't fit the data¶

On 04-01 the stock was $210, and the latest reported quarter was Q4'25. Compare that quarter to Q2'26:

	Q4'25	Q2'26	Change
Revenue	$10.27B	$11.54B	+12.3%
Operating income	$1.75B	$1.99B	+13.6%
Gross margin	54.3%	53.8%	–50 bps
Operating margin	17.1%	17.3%	+20 bps

The quarterly operating-income run rate rose 14% while the price rose 193%. That is multiple expansion, not an earnings inflection. If the answer is "forward expectations changed," I agree, but nothing in our packet shows those expectations: no guidance, no consensus, no segment data, and no news feed. The re-rating rests on something we can't see.

The margin story is also weaker than you present it: - Gross margin peaked in Q4'25. - Q1'26 operating income fell 16% QoQ. - The incremental operating margin from Q4'25 to Q2'26 is about 19% ($238M of added operating income on $1.27B of added revenue). That is roughly the average margin, so there is no visible extra leverage.

You also can't use the YoY comparison both ways. You called Q2'25's 39.8% gross margin "a one-off hit," and then you cited the swing from –$134M to +$1.99B in operating income as evidence of inflection. A large part of that swing is the base. And Q2'25 EPS of $0.54 came with $872M of net income on a negative operating income, so "normalized EPS is double last year's" compares two flattered numbers.

2. What you have to believe¶

You said the multiple compresses through growth. Here is that arithmetic. At 615.73 the market cap is about $1.0T, which is about 24x TTM revenue, about 155x TTM operating income, and about 158x TTM EPS. Even your own normalized run rate (about $1.05 a quarter) gives about 145x.

To hold today's price at a still-rich 30x earnings, EPS has to reach about $20.50, which is 5.3x TTM. At today's roughly 15% normalized net margin, that means revenue north of $200B, against $41B now. That is about 75% compounding for three years, or about 50% for four, only to earn zero from here. That is my arithmetic, and margin expansion would shrink the gap. But the last two quarters show margins plateauing, not expanding.

You asked for my forward earnings path. I don't need one. Even if earnings double, you're paying 75x.

3. Cash quality is thinner than "130% of net income"¶

TTM FCF of $8.4B is a 0.8% yield on a $1T market cap. Subtract about $1.9B of stock comp and it is about 0.65%. A headline says long yields hit their highest since 2002 (unverified), and either way this asset sits far below the risk-free rate.
Q2 operating cash flow of $2.37B included a $2.27B payables increase. Without it, OCF would have been roughly $100M. You called payables "timing" in your favor elsewhere. Timing reverses.
Receivables rose 21% QoQ against 12.5% revenue growth, and DSO went from 54 to 57 days. That is revenue growing more slowly than the receivables it creates.
Inventory is about 144 days of cost of revenue.
Capex is 3x YoY and leases jumped from $647M to $1.05B. You call that confidence, but it is cash spent ahead of revenue that hasn't arrived.
Buybacks fell from $524M in Q2'25 to $207M, which is 0.02% of market cap. The stock-comp bill is about $1.9B a year. The 1.8% dilution isn't "small" at this valuation: it is about $18B of value.

4. The tape is less orderly than you say¶

Four sessions is not a base. The real base was June to August, a 430–580 range. The stock is only 6% above its 06-30 closing high of 580.91 after three months.
This stock has already shown what a bad week looks like. It fell from 552 on 07-22 to 429.56 on 07-29 (–22% in five sessions) and was down 26% from the 06-30 high. With ATR at 3.9% a day, that is the normal temperament here, not an outlier.
ADX was under 20 until 09-17. The "every trend marker agrees" picture is two weeks old, and ADX has already fallen from 43 to 29.
The stretch readings are all at the top of the range. The weekly z-score is +2.14, the monthly TD sell setup is at 7 of 9, MFI is about 76, and price is 20% above the 50 SMA and 65% above the 200 SMA. Saying "no completed TD 9, so no exhaustion signal" means waiting for confirmation that arrives after the move.
The risk/reward is symmetric at best. The upper Bollinger band is +9.9% away. The daily SuperTrend stop (558.12) is –9.4%, the 50 SMA is –17%, and the 200 SMA is –40%.

Your own trade frame, with a stop 36–48 points below and a "deeper zone" 6–10% lower, describes a momentum trade. That isn't an investment case for a $1T company.

5. Macro and what's missing¶

Your macro evidence is one day of headlines that nobody could open. The same packet says the indexes had to "stage a comeback," that Accenture's move "dispels AI demand fears" (so the fears existed), and that Fed officials say inflation is "still too high." Accenture and IBM are IT-services names, not GPU demand. Gundlach calls the market "a hollow tree." A name at 24x sales has the most duration of anything in the market and the most to lose from a higher discount rate.

Our packet also lacks: - AMD's segment mix. - Any customer-concentration data. - Guidance. - The MI-series competitive position against Nvidia. - Export-control status.

On that last one, the 2025 gross-margin hit shows how policy can reach the P&L overnight. Sentiment and news came back empty. Your bullish case is consolidated financials plus a chart.

Insiders sold about $106M since August 1 into a 35% rally, with no buyers. I'll concede that's weak evidence, since the sales may be plan-driven. But nobody inside is leaning in either.

Bottom line¶

AMD may well be a great company, and I'm not claiming otherwise. At $615 you are paying for years of 50%-plus compounding up front, while the quarterly run rate has grown 14% in two quarters. Q3 ended 09-30, and a stock priced for acceleration is walking into a print with a 3.9% daily ATR and a precedent for –22% weeks.

What would change my mind: 1. Q3 operating margin clearly above 18–19%, showing real incremental leverage. 2. Receivables and DSO normalizing. 3. Guidance that implies sequential growth well above the last two quarters. 4. A reset to the 50 SMA area, about $510, where the multiple at least stops being absurd.

Until then, I wouldn't initiate here, and if I owned it I'd be trimming into strength. Bear Analyst: # Bear Rebuttal: Your Best Case Roughly Round-Trips, and Your Stop Isn't a Stop

You've conceded multiple expansion, the macro headlines, rates, the FCF yield and the base double-count. That narrows the debate. What remains is one claim, that opex discipline plus a good Q3 print justifies about $1T. I'll show why it doesn't.

Where you're right¶

Q3'25 is a defensible base. The 31% incremental margin is fair.
SBC is already in GAAP operating income. My $18B figure was rhetorical, and I won't stack it on top of the margin.
The treasury-method point on diluted shares may explain some of the creep. I can't verify it from the packet either.

1. Your own best case earns nothing¶

I'll grant your revenue path: 36% a year for four years, to about $140B. I think that is generous, but it isn't where I disagree. Using your two EPS outcomes and my multiples (my assumptions, not packet data), the return from $615.73 is:

4-year outcome	EPS	25x	30x	40x
Opex grows at ⅔ of revenue (your bull case)	~$20	$500 (–19%)	$600 (–3%)	$800 (+30%)
Opex grows at ~90% of revenue (recent pace)	~$15	$375 (–39%)	$450 (–27%)	$600 (–3%)

Four years of flawless growth and margin expansion break even at 30x. Positive returns need 40x on a $140B-revenue company. You said you aren't claiming a margin of safety, and this is what its absence looks like in numbers.

2. The opex assumption doesn't survive your own data¶

Your ⅔ ratio uses the base you dropped. It comes from the YoY comparison (32% opex growth against 50% revenue growth) off the Q2'25 base. You agreed to drop that base for operating income. On the sequential comparison you prefer, from Q3'25 to Q2'26, opex grew 22.5% against 24.8% revenue growth, a ratio of about 91%.
The 3.6-point operating-margin expansion since Q3'25 breaks down like this (my calculation from the packet):
Gross margin recovery: about 2.1 points. It has been flat to down since Q4'25 (54.3% to 53.8%), so that step is finished.
Shrinking Xilinx amortization: about 0.8 points. This is mechanical, not operating leverage.
Actual R&D plus SG&A leverage: about 0.6 points.
Reaching 30% needs far more leverage than that. With gross margin near 54%, opex and amortization must fall from about 36% of revenue to about 24%. At 0.6 points per three quarters, four years delivers roughly 3 points, not 10 or more.
Q2 alone was better, but one quarter doesn't settle it. Q2 opex rose 7.6% against 12.5% revenue growth, a ratio of 61%. But Q1 opex rose 3.5% on flat revenue, and SG&A grew 12% QoQ in Q2, the fastest-growing line. The three-quarter average is the honest number.
SBC is a risk to that ratio that I can't size. Under standard accounting, SBC is expensed at grant-date fair value over the vesting period. The stock has multiplied, so grants made at $500 or more will cost much more than grants made at $100–200. That pressure lands on the ratio you say decides the case.
Your 40% incremental margin starts from a trough. Q1'26 was the quarter operating income fell 16%, so 40% is rebound arithmetic.

3. "If Q3 passes, what's left?" The price is left¶

Take a passing Q3 on your terms: revenue of $12.5–12.9B (up 8–12% QoQ) at an 18.5% operating margin. That is $2.3–2.4B of operating income, or $9.2–9.5B annualized. At a $1.0T market cap, that is 105–110x. A clean pass moves the stock from 126x to about 108x annualized operating income.

Your tests protect against a thesis break. They don't produce a return.

The pass is also probably not a surprise. The stock rose 35% in four weeks (456.16 to 615.73) into this print. Neither of us can see consensus or guidance, and that is a hole in my case as much as yours. But the tape is the only expectations proxy we have, and it says the market is positioned for a pass. If the print passes, the stock earns little. If it misses, it takes the whole loss.

You called my $510 test "a price preference, not a thesis test." For an investor, price is the return. You said you'd add there yourself.

4. The invalidation level isn't a cap on losses¶

580.91 is about 1.5 ATR below the price, at the edge of noise, as you noted. A 3.9% ATR stock will tag that level on an ordinary bad week.
Earnings gaps jump over levels. The stock gapped 4.3% on 09-21 with no earnings at all. If the print disappoints, the gap sets the loss, not your close-below rule. "Reduce on a close below 580.91" is a plan for a market that trades continuously, and earnings don't.
The measured move to about 730 is a chart heuristic you've said isn't a forecast. The downside reference, the 50 SMA near $510, is –17%, and it is reached through a gap, not a stop.

5. A data-integrity note on cash¶

The packet doesn't reconcile. Payables (+$2.27B), receivables (–$1.25B) and inventory (–$423M) net to about +$0.6B, yet the report states total working capital was a –$730M drag. About $1.3B of other outflow is unexplained. Your "clean" $3.1B operating cash flow depends on that –$730M figure, and I can't tie it out. For the same reason, I won't build on my own "$100M" figure. What does hold is that Q2 operating cash flow leaned on a payables jump, and DSO is the line to watch.

Bottom line¶

We agree on more than the format implies: reduced size, add near $510, reduce on failure. The disagreement is the price paid for the option on Q3. You are paying 126x for a print whose clean pass gets you to about 108x. Your best-case math returns about zero over four years, and your worst case loses 27% at 30x.

My position stays the same. I wouldn't initiate here, and I'd trim if I owned it. I'll accept your three tests, and I'd add a fourth that addresses your crux: R&D plus SG&A below 33% of revenue in Q3 (34.1% now). Passing all four would remove the thesis-break risk, and I'd stop calling it a trim. It still wouldn't make $615 a good entry. At that price, a good outcome only gets you back to where you started. Bear Analyst: # Bear Closing: We Agree on the Tests, Not the Price

What I'll concede¶

Your 0.72 ratio is a fair YoY number. The Q2'25 distortion sat in cost of revenue, and R&D plus SG&A are clean. But you flagged the limit yourself: a depressed Q2'25 revenue base flatters it. I'd call 0.72 the ceiling and 0.91 the floor.
SBC is not a current problem. It fell from 4.8% to 4.4% of revenue. I'll keep your 5% flag as a watch item and drop it as an argument.
I can't see consensus. I won't use the tape as a proxy for expectations. The valuation math never needed it, so nothing below depends on it.
Your timing correction stands. Q3 is probably 4–5 weeks out, which matters for what follows.

Your table supports my case¶

R&D plus SG&A as a share of revenue over the last four quarters was 34.7%, 34.4%, 35.6% and 34.1%. That is 0.6 points of leverage in three quarters, inside a 34–36% band. Calling that "leverage arriving in steps" describes a ratio that has moved sideways. Q2 was good, Q1 was flat, and the average is the honest number.

Your 30% operating margin case needs total opex, including the $284M of amortization, to fall from about 36.5% of revenue to about 24%. At the current pace that is about 3 points in four years. The crux you named is the one metric that hasn't moved yet.

Passing the tests doesn't earn a return¶

You agreed a clean Q3 still leaves AMD at about 108x annualized operating income. Your plan to "move toward full size" on a pass means buying at that multiple. The four tests tell you whether the thesis is broken. They say nothing about whether the price pays you. Your own four-year table gives –3% to +30% at 30x, so a pass mostly protects you from a loss that was never the central risk.

The trigger table is a whipsaw¶

You add above 630.63 and reduce below 580.91. That band is about 50 points, or roughly 2 ATR, and the stock traded 596–631 in just the last week. A lot added at 631 and cut at 581 loses about 8% without any thesis change. A rule that buys strength and sells weakness inside two ATRs of noise bleeds in a range.

Sizing limits the loss but doesn't create edge¶

Sizing so a 20% gap is tolerable caps the downside. It doesn't make the bet positive expected value. At that size the base case also contributes little. You'd also carry about 24 sessions of exposure at about 3.9% ATR before any new information arrives. As a rough one-sigma, using ATR as a stand-in for daily dispersion, that is a high-teens percent range. You'd be paid for that wait only if the multiple holds.

The missing data arrives in weeks¶

You agree the packet has no backlog, guidance, segment mix, customer concentration or export-control status. Those decide whether the 34% growth pace survives. The Q3 report supplies most of them in a few weeks. The cost of waiting is real: if the stock runs to your ~730 measured move, I miss about 18%. I accept that. I'd rather pay up after seeing the data than before, because the price already assumes the data is good.

Where we stand¶

	Bull	Bear
Today	Hold small	No new position; trim if held
Pullback to ~510 with thesis intact	Add	Add
Break above 630.63	Add	Don't chase
Q3 passes all four tests	Move toward full size	Stop calling it a trim, but reassess at the then-price
Core disagreement	Controlled risk justifies owning the trend	Without a valuation cushion, owning it means betting on the multiple

The four tests are the right ones. Operating margin above 18–19%, DSO back toward 54, guidance implying sequential growth above recent quarters, and R&D plus SG&A below 33% of revenue would remove the thesis-break risk. They would still leave a stock priced so that four years of strong execution only gets you back to even. I'd rather own AMD at $510 on a pass than at $615 before one. Bear Analyst: # Bear Closing: The Plan Is Sound. The Price Is Still the Problem.

We now agree on the four tests, the pullback add, and the point that sizing limits losses but creates no edge. Here is where I think your last response still falls short.

What I'll concede¶

The opex ratio tracks revenue growth. Flat revenue in Q1 pushed it up 1.2 points, and a strong Q2 pulled it down 1.5. Averaging those into a "0.6-point trend" was too crude. I'm dropping it.
The exit multiple is an assumption. The 25x/30x/40x spread isn't data, and yours is a fair argument that a company still growing above 20% in year four may deserve more than 30x.
Volatility cuts both ways. I've already conceded I could miss about 18% if the measured move plays out.
Your plan is better. Dropping the 630/581 whipsaw and the "full size on a pass" language fixes the weakest parts of your earlier plan.

1. If leverage is a revenue story, one quarter can't settle it¶

You say opex growth is roughly fixed at 3.5–8% a quarter, so the ratio falls only when revenue outruns it. I agree, but that changes what "Q3 answers the crux" means. The thesis then isn't opex discipline. It's whether revenue keeps compounding at about 34% for years.

A passing Q3 tells you Q3 happened. It doesn't tell you about backlog, customer concentration, segment mix, export controls or competitive position against Nvidia. Your own concession is that the packet has none of this. The data that would justify four years of compounding isn't in the quarterly print either, except possibly in guidance.

2. Your likely path is the $15 row, not the $20 row¶

You said the ⅔ opex ratio is "not obviously achievable." That puts your realistic case on the $15 EPS path, and your table says what it pays:

4-year EPS	25x	30x	40x
~$15 (your likely case)	–39%	–27%	–3%
~$20 (your bull case)	–19%	–3%	+30%

Even the bull case at 40x on $140B of revenue is about 7% a year, with a stock that moves 3.9% on an average day. I can't verify the risk-free rate, and the 10-year headline is unconfirmed, so I'm not leaning on it. Still, that is a thin payoff for this much dispersion.

Volatility is two-sided, but the scenario table is not. Your upside needs your best operating case plus a premium multiple, and your downside only needs your likely case plus a normal one.

The measured move to about 730 is worth a look too. On a passing Q3 (about $9.35B annualized operating income), a $1.19T market cap is about 127x. That is today's multiple. The upside case is the re-rating repeating itself after a pass, not growth catching up.

3. The tests are a reason to wait, not to hold¶

You said a failed test "is exactly how a 20% gap happens," so the tests protect the left tail. They do, but only for someone who acts after seeing them. If you hold through the print, you take the gap unconditionally. If you wait, you get the same information and skip the gap.

Your exit rules show the same problem: - "Cut below 558" and "exit if Q3 fails two tests" both execute after the gap. - The only protection that works through the event is size. - You've already agreed size creates no edge.

So the plan comes down to paying four to five weeks of event risk, at about 3.9% a day, for trend persistence. That edge is real but modest, and it sits on a chart with a weekly z-score of +2.14, a monthly TD count of 7 of 9 and ADX falling from 43 to 29. Those are stretch signals, not sell signals, and I won't pretend otherwise. They don't help your case, though.

4. The catalyst we can't see¶

The 09-21 gap came on 44.5M shares, with no earnings and no news in our packet. Something moved the stock that neither of us can name. That cuts against both of us: - You can't call the breakout "confirmed" without knowing what it priced in. - I can't call it priced in without the same knowledge.

That is why I won't use the tape as evidence for either side. It is also why I'd rather let the next report supply the missing data than guess at it with a position.

Where we end up¶

	Bull	Bear
Now	Hold small, sized to survive a 20% gap	No new position; trim if held
Pullback to ~510, thesis intact	Add	Add
Q3 passes all four tests	Add, scaled to price against the return table	Reassess at the then-price
Q3 fails two or more	Exit after the gap	Already out of the way

Your "scale to the price against the return table" is where our views meet. At 108x on a pass, that table supports only a small position. Holding a small position isn't an unreasonable view, and I can't call it wrong. But "small" and "none" differ only by the cost of waiting.

Bottom line¶

AMD has genuine growth, a net-cash balance sheet and a business that may be executing very well. None of that gives you a valuation cushion at about $1.0T.

My position hasn't changed. I wouldn't initiate at $615, I'd trim if I owned it, and I'd add at about $510 or on a clean Q3 at a price that pays for the risk. I'd rather buy AMD after the data than before it, and give up some upside for that. Bear Analyst: # Bear Final: Fair Trade-Offs, but the Central Case Still Doesn't Pay

What I concede¶

Your two exits cover two different risks. The 558 rule addresses drift over about 24 sessions of continuous trading, and size addresses the gap. I lumped them together, and that was wrong.
Waiting reduces variance and doesn't create edge. If gaps are fairly priced, I skip both tails. My case rests on the price paid, not on dodging the gap.
Waiting can turn into never. If the stock runs on a pass and I won't chase, I miss it. That is the cost of discipline, and I accept it.
$15 is a floor case, not your central one. Your $17 is the fairer estimate.
The stretch signals aren't sell signals. A weekly z-score of +2.14, a monthly TD count of 7 and a fading ADX describe a mature trend, not a reversal. The tape's tendency to persist is your one real edge, and I won't deny it.

Where I still hold¶

1. Your central case is a coin flip on the multiple. At $17 EPS, the four-year outcomes from $615.73 are:

Exit multiple	Price	Return	Per year
30x	$510	–17%	about –4.6%
35x	$595	–3%	about –0.9%
40x	$680	+10%	about +2.5%

Only a 40x multiple earns anything, and then about 2.5% a year. You said the packet gives you no way to defend a better multiple. So the argument for holding isn't that the stock pays you. It's that the trend might carry it for 24 sessions.

2. Your three reasons to hold describe the business, not the price. Fifty percent growth, a 17.3% operating margin and a net-cash balance sheet are why AMD trades at about 126x annualized operating income, not reasons it will earn more from here. You called them reasons to hold, not to add. If they were an edge at $615, they would justify adding too.

3. You're mixing horizons. The four-year table says the stock offers a thin return. The 24-session hold rests on trend persistence, which is a trading thesis. That can be a legitimate position, but it isn't the investment case for a $1T company that your plan presents it as. It should be sized and judged as a trade.

4. My $510 add isn't a bargain either. On your $17 EPS, $510 is the 30x break-even. At that price the table is balanced, not cheap, and returns still depend on a multiple above 30x or on EPS beating $17. My claim is that a clean Q3 should revise the EPS path, and that $510 is where the risk and reward stop being lopsided. If Q3 doesn't raise the path, I'd size that add moderately too.

Where we end up¶

	Bull	Bear
Today	Hold small, cut on a close below 558	No new position; trim if held
Pullback toward 510, thesis intact	Add	Add, moderate size unless Q3 raises the EPS path
Q3 passes all four tests	Add, scaled to price against the return table	Reassess against the table at the then-price
Q3 fails two or more tests	Exit after the gap	Already out of the way

Bottom line¶

We agree on the four tests, on sizing as the only tool for gap risk, and on the pullback add. The remaining difference is narrow. You'd hold a small position through the print for the trend, and I wouldn't, because your own central estimate returns about zero to negative at any multiple I can defend. Neither of us can resolve the missing data (guidance, segment mix, customer concentration, export-control status) before Q3. Waiting for it costs me some upside, and holding costs you a bounded loss if the multiple compresses.

I'd rather pay for the data than for the guess. If the stock runs to the 730 measured move without me, I'll have missed about 18%, and I'll have missed it knowing that 730 on a clean Q3 is again about 127x annualized operating income.

Research Manager¶

Recommendation: Underweight

Rationale: This debate ended closer together than usual. Both sides agree on the four Q3 tests, on size being the only protection against an earnings gap, and on adding near $510. What's left is whether to hold a small position through the print or none at all. Both of those are below a standard allocation, so the call is about how much to trim, not which direction.

What the bull proved: the business is real. Revenue is up 50% year over year to $11.54B. Operating margin is 17.3%, a cycle high. Gross margin has held at 52–54% for four quarters. TTM free cash flow is about $8.4B, net cash is about $8.8B, and the 09-21 breakout came on heavy volume with the trend still intact. The bull also correctly showed that the operating-expense ratio rises and falls with revenue growth rather than following a time trend, and that the exit multiple is an assumption, not data.

What the bear proved, and the bull conceded: the 193% re-rating since April came almost entirely from a higher multiple. Quarterly operating income rose 14% from Q4'25 to Q2'26, while the multiple on annualized operating income went from about 49x to about 126x. The bull's own central estimate is about $17 EPS in four years, which gives -17% at 30x, -3% at 35x and only about +2.5% a year at 40x. A clean Q3 still leaves the stock near 108x annualized operating income. Q2 operating cash flow leaned on a $2.27B payables increase. Receivables grew faster than revenue, with DSO rising from 54 to 57 days. The ~730 measured move just repeats today's multiple. The bull withdrew the macro support, the "confirmed breakout" claim, and the cash-flow figure that adjusted for working capital.

Why this rating: the bull's remaining argument is trend persistence over about 24 sessions. The bear correctly called that a trading thesis, not an investment case for a $1T company. The bull also conceded there is no valuation edge, and that his three reasons to hold describe the business, not the price. The bear's case on price carries the argument. It isn't a Sell, though: the fundamentals are strong, the balance sheet is clean, and the trend is intact, so a small position is defensible.

The packet has no guidance, consensus, segment mix, customer concentration, export-control status, competitive data or confirmed earnings date. That limits conviction both ways and is why the plan relies on Q3 results.

Strategic Actions: 1. Trim to about 30–40% of a standard allocation now, selling into strength rather than on down days. If you hold nothing, don't start a position above about $600. If you want token exposure, cap it at 25% of standard. Size it so a 20% earnings gap is tolerable at the portfolio level, since stops won't protect through a gap. 2. Don't add before the print on price strength. That includes a close above 630.63, because the 581–631 band is about 2 ATR of noise and buying breakouts inside it loses money in a range. 3. Before the print, exit the rest on a daily close below 558, which is the daily SuperTrend and the bottom of the 09-21 gap. That covers drift, given ATR of about 23.8 points (3.9%) and the July drop of 22% in five sessions. 4. On a pullback to $510–530 (near the 50 SMA) with no thesis damage, add back to about 60% of standard. That price is only break-even at 30x on $17 EPS, so it isn't a full-size entry. 5. Q3 is likely late October or early November, unverified. Judge it on four tests: (a) operating margin above 18–19%; (b) DSO back toward 54 days; © guidance implying sequential growth above the recent run rate; (d) R&D plus SG&A below 33% of revenue, versus 34.1% now. Also watch operating cash flow excluding payables, and stock-based compensation, which is 4.4% of revenue now and a concern above 5%. 6. If all four tests pass, scale toward 75–100% of standard, depending on the price after the print against the four-year return table. Don't chase at multiples above about 110x annualized operating income. 7. If two or more tests fail, for example operating margin below 17%, the opex ratio above 35%, DSO at 57 or higher, or flat guidance, exit the remaining position. 8. If you get guidance, segment mix, data-center commentary or export-control news before the print, re-run this plan with it.

III. Trading Team Plan¶

Trader¶

Action: Sell

Reasoning: The research plan is Underweight, which maps to a Sell sized as a trim, not a full exit. The 193% re-rating since April came almost entirely from the multiple: quarterly operating income rose about 14% while the multiple on annualized operating income went from about 49x to about 126x. The bull's own ~$17 EPS estimate gives roughly -17% to +2.5% a year at 30-40x. The technicals support selling into strength: the weekly z-score is +2.14, the monthly TD count is -7 of 9, ADX has faded from 43.11 to 29.41, and MFI is about 76. The trend is still intact (all three SuperTrends up, price above the 10 EMA, 50 SMA and 200 SMA), and the business is strong, so I would keep a small core position through the Q3 print and not exit fully. Exit the remainder on a daily close below 558, the daily SuperTrend and the bottom of the 09-21 gap. With ATR at about 23.8 (3.9%), a stop any tighter would be noise. No guidance, consensus, earnings date or export-control data is in the packet, which limits conviction in both directions. Portfolio holdings were not provided, so the sizing is expressed relative to a standard allocation.

Entry Price: 616.0

Stop Loss: 558.0

Position Sizing: If you hold AMD, trim to about 30-40% of a standard allocation, selling into strength near 616-631 and not on down days. If you hold none, do not start above about $600. Token exposure is capped at 25% of standard. Size the remainder so a 20% earnings gap is tolerable at the portfolio level, since stops won't protect through a gap. Add back to about 60% of standard only on a pullback to $510-530 with no thesis damage. Scale toward 75-100% only if all four Q3 tests pass: operating margin above 18-19%, DSO back toward 54 days, guidance implying above-trend sequential growth, and R&D plus SG&A below 33% of revenue. Exit the remainder if two or more tests fail. Do not add before the print, even on a close above 630.63.

FINAL TRANSACTION PROPOSAL: SELL

IV. Risk Management Team Decision¶

Aggressive Analyst¶

Aggressive Analyst: Neither of you has spoken yet, so I'll take the arguments I expect and answer them up front.

The conservative case will be "you're not being careful enough, exit everything." The neutral case will be "the trend is intact, the data is thin, so hold and wait for the print." I think both are the comfortable positions, and neither is the best risk-adjusted one.

Start with what actually drove the move. AMD went from about 210 to 616 since April, up 193%. Quarterly operating income, measured against the Q4'25 print that was current in April, rose about 14%. The multiple on annualized operating income went from roughly 49x to roughly 126x. This is a re-rating, not an earnings story. Even the bull's own $17 EPS number, at 30-40x, gives somewhere between about minus 17% and low single digits a year from here. When the optimistic case barely clears flat, the bold move is to sell into strength and recycle the capital, not to hold and hope.

To the neutral analyst, who will say the trend is intact: I agree. All three SuperTrends are up and price is above every average. That is exactly why I keep a core position and don't go to zero. But the strength underneath is fading. ADX has dropped from 43 to 29, volume has fallen from 44.5M on the breakout day to the high teens, MFI is about 76, the weekly z-score is +2.14, and the monthly TD count is 7 of 9. Price sits 20% above the 50 SMA and 65% above the 200 SMA. A trend can stay intact right up until it stops being intact, and the plan has a defined exit for that: a daily close below 558.

To the conservative analyst, who will want a full exit: a full exit gives up the one thing that could prove me wrong. This stock gapped up on volume, it is above every trend marker, and the upper Bollinger band is near 677. If it squeezes there, a trimmed position still participates. Look at the asymmetry. If I sell about two-thirds and the stock runs 10%, I lose about 6.5% of position value in upside. If it gaps 20% down, which is not hypothetical because it fell from 552 to 430 in five sessions in July, I avoid about 13%. And the plan has a re-entry at 510-530 with a larger position, so I'm not leaving the trade. I'm setting up to buy it cheaper.

Now the data gaps. The neutral side will say we have no sentiment, no company news, no earnings date and no guidance, so we shouldn't act. I'd flip that. Missing information is a reason to size for uncertainty, not to freeze at full size. Holding a full allocation into an unknown print is itself a bet, and the biggest one on the table. The plan sizes the remainder so a 20% gap is tolerable at the portfolio level. That is how you act under uncertainty.

The fundamentals give me more than the neutral analyst will admit. Q2 EPS of $1.38 was lifted by a $483M investment gain and a 9.8% tax rate, and the normalized figure is closer to $1.00-1.10. Free cash flow fell 39% quarter on quarter as capex doubled to $808M. Receivables jumped 21% and DSO went from 54 to 57 days. Payables flattered operating cash flow and could reverse. Buybacks of $207M didn't even cover $503M of stock comp. And insiders have sold about $106M since August with no open-market buys since May 2025. I'll concede that most of that looks like planned selling, so I'm not calling it a bearish signal. But nobody inside is buying at 126x.

Here is the part I find most persuasive. The plan has four Q3 tests: operating margin above 18-19%, DSO back toward 54, guidance above trend, and R&D plus SG&A below 33% of revenue. On Q2's numbers, margin is 17.3%, DSO is 57, and opex is 34.1% of revenue. That is three of four failing today, before we even see guidance. The stock is priced as if all four pass, so it needs to improve on every front to justify 126x.

I'll own the macro risk too. Chips rallied on 10/1 and yields fell, but the headlines also include hawkish Fed commentary and a possible 10-year at a multi-decade high, which I couldn't confirm. A 126x multiple is the most rate-sensitive thing in the portfolio.

So my case is that trimming here is the high-conviction, high-reward play. It takes profit on a 193% move, keeps exposure to the trend, has a defined stop, and holds dry powder to buy aggressively at 510-530 or scale to 75-100% if the print earns it. The comfortable calls are to hold everything or to leave entirely. I'd rather make the call that works whichever way the print goes.

SELL, as a trim, with the core held through the print. Aggressive Analyst: I'll give up some ground first, because you've both earned it.

The valuation bracket was my arithmetic error. $17 at 30x is about 510 and at 40x is about 680, so the range is roughly minus 17% to plus 10%, not low single digits. But the bull's own EPS is already about 4.4 times trailing EPS of $3.89, and it still gives a range centered near zero from a stock at 126x. Neutral says that argues for a smaller position, not none. I agree, and that's what a trim is.

Neutral is also right that the 14% depends on the window, and that margin and opex are close to one test, since gross margin less opex less amortization reconciles to the reported 17.3%. I'll count them as one. Passing is attainable too. A 9-10% sequential revenue gain was cleared in three of the last four quarters. But the fourth was flat, and at 126x a flat quarter changes the whole picture. The stock rose 2.9x while reported operating income rose 14% against the April baseline. For forward estimates to justify that, they would have had to move enormously. The 44.5M-share gap day may well have been news we can't see, but the packet doesn't prove it, so the burden stays on the holder.

Conservative is right about July. A drop from 552 to 430 over five sessions is a slide, not a gap, and that's where the 558 stop earns its keep. Size is what covers a gap and the stop covers a slide, so the plan needs both.

On depth, I'd put the 15-25% versus 30-40% debate in perspective. The difference is about 13% of the position, which is roughly 1.3 points on a 10% run and 2.6 points on a 20% gap. Neutral's gap budget settles this better than either of us. Size the remainder so a 25% gap costs about 1% of the portfolio, which means roughly 4% or less. If 30-40% of standard passes that test, keep it. If not, go lower.

I still don't want to go to the low end or exit, because of the clean-print case. Neutral is right that a clean print at this multiple may gap up, and then "rebuy after the print" means buying at a higher price. The core is the only piece that participates in that. A full exit is also irreversible in a way a trim isn't, and in a taxable account with a low basis it's expensive. I can't see the account, but if that applies, it argues against going binary.

Neutral caught two real contradictions in the re-entry. "No adds before the print" and "add at 510-530" can't both stand, and buying back 60% after exiting a smaller core on a 558 break makes no sense. I'm fixing both: - Before the print, any add is capped at the size I trimmed. - After a 558 exit, re-entry is a fresh decision. It needs stabilization and starts at 30-40% of standard. - The 60% and larger sizes are for after a print that earns them.

Conservative is also right that 105x at 520 isn't cheap. The add is about the 50 SMA near 512 and a better risk/reward, not value.

I'll accept neutral's staging with one change. Sell about half the trim now, since 615.73 is already inside the 616-631 zone and waiting for a retest may never pay off. Sell the rest on a close below both 599 and 596, or into strength toward the upper band near 677. Add a deadline, so that whatever hasn't been sold about a week before the print goes regardless. The earnings date is unverified, so confirm it first. Neutral is also right that weak guidance should halve the remainder, and weak guidance plus another failure should exit it. Conservative's exit on guidance alone is too blunt for a stock that can fall on fine guidance.

I overclaimed when I said the plan works whichever way the print goes. It doesn't. If the stock runs to 700 and never revisits 510-530, I've given up roughly 6-7 points of position value per 10% of upside, and I'm adding later at higher prices. In exchange, a 20% gap costs the remainder, not the whole position. The plan isn't free of regret. It has the least regret across the outcomes I can't rule out, with the sizing set by the gap budget and no information edge on the print.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to a gap-budgeted remainder of up to 30-40% of standard, with the core held through the print. Aggressive Analyst: I think we've converged enough that the fight is now over a few numbers, so I'll concede what's earned, push back where I still disagree, and say where I land.

On sizing, Conservative is right that 25% is a soft stress case. The July slide was about 22% when the stock was far cheaper, the lower band is about 29% below price, and at 126x a 30% drop on a bad print is plausible. I'll take 30%. It costs me little. On a 1% budget, the difference between a 25% and 30% stress is a remainder of 4% versus 3.3% of the portfolio. In the bad case that is about 0.2 points of portfolio loss, and in a clean-print run it is a similarly small amount of upside. That is the whole sizing fight, and I'm not defending a 0.7-point difference. Neutral's lesser-of rule settles it: the remainder is the lesser of 30-40% of standard or what passes the budget at a 30% stress. Where Conservative says it should land at the low end or below, I'd say nobody here can know that without knowing what standard means.

I also concede the pre-print add. Capping adds at the trimmed size would let me buy the whole trim back at 510-530 and walk into the event at full size. The cap should be the budget size. Since the remainder is already at that size, the practical result is no adds before the print. After a 558 close, I'll skip re-entry until the print instead of re-entering on stabilization. The 510-530 level becomes a post-print tool, for a pullback with the thesis intact. I'll also say plainly that it's a structural entry, not a value entry, since 105x at 520 isn't cheap.

On staging, I'll take Conservative's point that the 599/596 level is a trigger to finish a trim, not a stop on the core, so whipsaw costs little. I'll take Neutral's limit at 650-660 for the second half, just above the 639 high, because waiting for 677 means carrying excess exposure to ask for 10% more. A fixed date is the one mechanical rule I want, because it protects me from my own habit of waiting for one more leg. I'd use five trading days before the report if it's confirmed, and about October 21 if it isn't. Lots sell highest-basis first, with an eye on holding periods if any are short-term.

Here is where I still push back. Conservative's asymmetry argument is that a missed rally can be rebought but a gap loss can't. That proves too much, as Neutral noted. If gap risk is the only thing that counts, the answer is zero, and nobody is arguing for zero. Rebuying also isn't free, because a clean print at this multiple may gap up and I'd be buying higher. The core is the only part of the plan that participates in that outcome. It's also the bold part. Selling most of a 193% run at 126x is the contrarian call, and holding a budgeted remainder through the print is what keeps us in the trade if the market keeps paying up. A plan where every disagreement resolves toward less risk is an exit by committee.

I like Neutral's options idea, with two cautions. The implied move gives the expected size of the reaction, not the tail, so I'd use it to sanity-check the 30% stress and not to replace it. I also have no quotes, and premium will be inflated going into earnings on a name that moves about 3.9% a day. If a put spread covering a 30% gap is affordable, it could justify keeping a little more than the budget size. That has to be priced first, not assumed. A tight collar on a heavily appreciated position can also be treated as a sale for tax purposes, so check that before relying on it.

My plan is to sell about half the trim now near 616. I finish on a 650-660 limit, a close below both 599.43 and 596.07, or the deadline, whichever comes first. The remainder is the lesser of 30-40% of standard or the 30%-stress budget. The core exits on a daily close below 558, with no re-entry before the print and no adds above budget size. After the print, margin and opex count as one test, so there are three. Weak guidance halves the remainder, weak guidance plus another failure exits it, and a clean pass scales back in stages toward 75-100%.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the core held under a 558 close. Aggressive Analyst: I'm not going to relitigate what's settled: the lesser-of rule, the 30% stress, half now, the 650-660 limit, the date backstop, no adds or re-entry before the print, and three tests instead of four. I'll retire "exit by committee," and I accept Neutral's point that a budget-sized remainder isn't the bold part. The bold part is what we do after a clean print, and I think the plan is still missing that.

Conservative, you called the rebuy cost an option premium. Follow that through. If we've paid the premium, we don't then refuse to exercise. Suppose margin comes in at 18-19%, guidance is above trend, and the stock gaps 15% to around 700. The plan has to say now that we scale back in at 700, not wait for 510-530 to come back. Otherwise we'll anchor on our sale price, call the new price too high, and sit at a fraction of standard while the thesis works. So a clean pass means buying back in stages at whatever price the market gives us, each stage conditioned on the stock holding its post-print gap, not on a level.

One correction to the analogy: the premium is bounded by the fraction we sold, but it isn't known. An option premium is quoted up front. Ours depends on how far the stock runs, and nobody here has an edge on that. So I'd say the cost is acceptable, not that it's priced.

Neutral is right that the 1% budget is a preference, so let's make the sizing checkable. With the cap at about 3.3% of the portfolio, the whole 30-40% range passes if a standard AMD allocation is below roughly 8% of the portfolio. Above roughly 11%, even 30% of standard exceeds the cap, and the budget sets the size. In between, the cap clips the top of the range. That tells whoever holds this which side of the rule they're on without us guessing at their book.

On timing, the packet describes the print two ways. The news report says "late October or early November" and the fundamentals report says "likely early November." Neither is verified. Confirm it this week. If it's confirmed for November, the deadline is five trading days before it. October 21 should only apply if we still can't confirm a date by mid-October. Otherwise the fallback could force the sale two weeks early just because nobody checked a calendar.

Conservative is right about the open. The 558 rule has the same issue: it triggers on the close and executes at the next open, so the core is exposed to a gap through 558 too. That's why the remainder is sized against a 30% stress and not against the distance to the stop.

On options, I'd look early, not the day before the print. Implied volatility usually builds into earnings, so a hedge priced the week of is typically dearer than one priced once the date is confirmed. Until there's a real quote, it adds nothing to size. I'm also weighting the macro headlines lightly. Chips rallied and yields fell on 10/1, but the 10-year-at-a-multi-decade-high headline is unconfirmed and the Fed commentary is hawkish. Nothing in the plan hangs on either.

The plan is: - Sell about half of the trim now at a limit that fills, highest-basis lots first. - Finish at the first of a 650-660 limit, a close below both 599.43 and 596.07, or the deadline. - Size the remainder at the lesser of 30-40% of standard or the 30%-stress budget. - Exit the core on a daily close below 558. - Add nothing and re-enter nothing before the print. - After the print, count margin and opex as one test. Weak guidance halves the remainder, weak guidance plus another failure exits it, and a clean pass scales back in stages toward 75-100% at whatever price the market gives us.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the remainder exited on a daily close below 558 and a pre-committed scale-back if the print earns it. Aggressive Analyst: Most of what's left is about the post-print rules, so I'll take those.

Conservative, you're right that a clean print confirms the quarter without making the stock cheap. An 18.5% margin on 9-10% sequential growth is about $2.3B a quarter, or $9.3B annualized, and a stock gapping to 700 would still be around 120x. So I'm dropping "march to 75-100%" as a promise. It's a ceiling the evidence has to climb toward, and the first stage back is modest. Neutral's point also holds that 120x is one quarter annualized, which is a floor for a company growing revenue about 50% a year. Guidance is what tells us how far above the floor the forward numbers sit, which is why it's a test.

I also take the qualifier on what counts as a pass. If free cash flow is down only because payables unwound while DSO improved, that's a watch item. If DSO is still climbing and operating cash flow excluding payables is weak, stage two is blocked. Q2's soft spots were receivables, payables and capex, and the pass criteria should cover them. I accept the cluster point as well. If the caller holds other AI or semiconductor names, the budget applies to the whole group. That argues for trimming AMD first, since it carries the worst multiple in that group.

Where I disagree is the claim that the budget never loosens until a second clean quarter. Neutral's 1.5% cap at a 30% stress gives about 5% of the portfolio, and 5% times the 22% July slide is about 1.1%. So that isn't loosening the budget. It's matching the stress to the risk that's left once the known event is behind us. After a pass, the risk is a non-event drawdown like July, not an earnings gap. If the cap stays at 3.3% until another quarter reports, most people's scale-back language becomes decoration. A pass should move the cap to about 5%, with each stage still having to hold its gap. Past 5% it waits for a second clean quarter or a reset in the multiple. If standard is above 5% of the book, the position doesn't get back to standard for months. That's the honest cost of a 126x stock, and I accept it.

On holding conditions, I'll take Neutral's: stage one after three sessions above the pre-print close, stage two after another week above the post-print low. If the stock falls on a clean print, we wait, and 510-530 becomes a legitimate structural entry again. I still insist the trigger is evidence plus a hold, not a price level. Otherwise we anchor on 616 and refuse to buy at 700 even when the print and guidance earned it.

Conservative's interim-exposure point is the best new one. Selling half the trim now leaves roughly 65-70% of standard for three to four weeks, above the budget size. I'm choosing that cost, and it isn't free. It only works if the first tranche fills. Use a limit within about half an ATR of the last close, so around 604 or better, and if it doesn't fill within two sessions, reprice. The 596 trigger is about 3% below the last close and should catch a July-style slide. A close below both 599.43 and 596.07 is in practice a close below 596.07. An overnight macro gap isn't covered. We accept that for a bounded window, and the date backstop keeps the window bounded.

We still have no sentiment data, no company news, no verified earnings date, and no idea what the caller holds. The plan is conditional on the caller checking those, and sized relative to their own standard allocation and book.

The plan is:

Sell about half the trim now with a limit that fills, highest-basis lots first, and check holding periods.
Finish on the first of a 650-660 limit, a close below 596.07, or five trading days before a confirmed print. Use about October 21 only if the date is still unconfirmed by mid-October.
Size the remainder at the lesser of 30-40% of standard or the 1% budget at a 30% stress, applied across the whole AI and semiconductor cluster.
Exit the core on a daily close below 558, executed at the next open.
Add nothing and re-enter nothing before the print.
After the print, count three tests with DSO and cash flow as qualifiers. Weak guidance halves the remainder, and weak guidance plus another failure exits it. A clean pass rebuilds in held stages up to about 5% of the portfolio.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the remainder exited on a daily close below 558 and a staged, budget-capped scale-back only if the print earns it.

Conservative Analyst¶

Conservative Analyst: I'll start with what I agree on. The aggressive analyst has pre-argued a conservative case that I'm not entirely making. I'm not saying the trend is broken. All three SuperTrends are up, OBV sits next to its high, and the last four sessions look like orderly digestion on light volume. My argument is about size. We're being asked to carry the biggest unscheduled event in the portfolio through a window where we have no earnings date, no guidance, no consensus, no sentiment and no company news. I think the plan keeps more exposure through that than it should.

Take the aggressive analyst's own scenarios. If we hold a third of the position and the stock runs 10%, that third adds about 3.3% of the original position. If it gaps 20%, it costs about 6.7%. Holding it only pays if the good outcome is roughly twice as likely as the bad one, and nothing in the packet gets us there. The aggressive analyst says missing data is a reason to size for uncertainty. I agree, and that argues for a smaller remainder than 30-40% of a standard allocation.

The stop is also weaker protection than the plan implies. A daily close below 558 is about 9% away on a stock that moves roughly 3.9% a day, and the plan admits stops don't help through a gap. The July episode is cited as a gap, but it was a five-session slide from 552 to 430, which a stop might have helped with. An earnings gap is what a stop can't help with, so the only real protection against it is position size.

I'm also not comfortable with the re-entry at 510-530 at a larger size. That's called buying it cheaper, but by the aggressive analyst's own arithmetic the stock is still around 105x annualized operating income at 520. It's less expensive, not cheap. A price-only trigger would also put us back in bigger if the market is repricing the whole thesis. I'd want the print to earn the re-entry, not a level.

On the four Q3 tests, I'd be fair. They're Q3 tests, and margin went from 14.4% to 17.3% in one quarter, so I wouldn't count three failures today. The point is that the stock is priced for every one of them to improve. I'd add what the cash flow shows. Payables contributed about $2.3B in a quarter where operating cash flow was $2.4B, while receivables and inventory absorbed roughly $1.7B. If payables normalize and capex stays near $800M, free cash flow gets thin quickly. Inventory is up 27% year on year at about 144 days, goodwill and intangibles are 49% of assets, and buybacks aren't covering stock compensation.

I tried to reproduce the valuation bracket. At $17 EPS and 30x you get about 510, roughly minus 17%. At 40x you get about 680, closer to plus 10% than low single digits. Even so, the best case is modest against a worst case that includes a 20% gap, and the stock is 20% above its 50 SMA and 65% above its 200 SMA. On macro, I'd give the "hollow tree" headline little weight, and the 10-year headline is unconfirmed. But a 126x multiple is rate-sensitive, and a rebound on a day yields fell can reverse the same way.

So I'd keep the Sell but make it deeper. I'd trim toward 15-25% of a standard allocation, or exit fully if this position is large for the portfolio or can't absorb a 20-25% gap. I'd also stop making the selling conditional on a retest of 616-631. If the stock closes below both the 10 EMA at about 599 and the 09-28 low of 596, finish the trim. I'd keep the 558 close as a backstop but treat size as the real protection. Re-entry should be earned by the print and capped at the trimmed size until then. Weak guidance on its own should be enough to exit the rest, since it's the forward-looking test and the stock is priced on the forward view.

If we're wrong, we miss some upside on a position that's already up 193%, and we can rebuy after a clean print. If the aggressive plan is wrong, we've held a third of a 126x stock through the print, and then bought more on the way down. Conservative Analyst: I'll start with what I'm willing to give up, because you've both moved toward the middle and some of your corrections are fair. Neutral is right that margin and opex are close to one test, so I'll count three independent tests, not four. I'll also drop my claim that weak guidance alone should clear the whole remainder, since a stock at this multiple can fall on fine guidance. And I'm not leaning on the technicals. ADX at 29, RSI at 67 and a daily z-score near zero say extended, not broken. My case never rested on them. It rests on a valuation that needs everything to go right, and on an event whose date, consensus and guidance we can't see.

Where I still disagree starts with the gap budget. I like it, because it's the first thing in this debate that turns an argument into a number. But 25% is too gentle as the stress case. In July this stock fell from 552 to 430 in five sessions, about 22%, when it was far cheaper than it is now. The 50 SMA is 17% below price, and the lower Bollinger band near 439 is about 29% below. At 126x, a 25% drop on a disappointing print is a plausible bad outcome, not a tail. Run the same 1% budget at a 30% stress and the remainder is about 3.3% of the portfolio. If a standard allocation is 10%, then 30-40% of standard is 3-4%, right at the edge with no cushion. So 30-40% shouldn't be the default. The range should be whatever passes the test, and I'd expect it to land at the low end or below.

Second, every post-print rule you've discussed (halve on weak guidance, exit on guidance plus another failure, scale up on a clean pass) executes after the report. The report comes after the close and the reaction happens at the open. None of those rules protect against the first move. The only tail protection is the size we carry into the print, which is why I keep coming back to it.

Aggressive, your fix on pre-print adds doesn't work yet. Capping adds at the size you trimmed means you can buy the whole trim back at 510-530 before the print. You'd be at full size going into the exact event you sold down to avoid. The cap should be the gap-budget size, not the trimmed size. You also conceded that 105x at 520 isn't cheap, so that add is about structure, not value. After a 558 break, I'd wait for the print before re-entering at all, instead of re-entering on stabilization.

On staging, I can live with half now. But the deadline for the second half is "a week before the print," and we haven't verified the print date. Anchor it to a calendar date, say mid-October, and move it only if the date is confirmed. Neutral, your 0.7 ATR point would matter if the 599/596 level were a stop on the core. Here it's a trigger to finish a trim to a size we've already decided is right. Getting whipsawed on a trim costs little, while being the wrong size on print day costs a lot. Waiting for 677 to sell the rest also means carrying excess exposure just to ask for another 10%.

On taxes and irreversibility, taxes are real but they're a timing cost. You owe them whenever you sell, and a drop shrinks the gain as well as the proceeds. That's a reason to sell the highest-basis lots first, not a reason to keep risk. And the two mistakes aren't symmetric. If we trim and the print is clean, we miss upside on a portion and can rebuy in stages, and the remainder still participates. If we're full size into a 25-30% gap, that's a loss of capital we can't rebuy. A regret-minimizing plan should weight those differently.

Neutral, your bracket of minus 17% to plus 10% is built on the bull's own $17 EPS, which is 4.4 times trailing. That's the optimistic case, and its midpoint is already negative. The 44.5M-share gap day cuts both ways. If it was news, it's already in the price, and the stock now has to beat expectations nobody here can see.

Finally, the quality issues point the same way. Receivables rose 21%, payables of about $2.3B nearly equaled operating cash flow of $2.4B, free cash flow fell 39%, and buybacks of $207M didn't cover $503M of stock comp. None of that says the business is bad. It says Q3 can look messy on cash flow even if revenue is fine, and 126x leaves no room for a messy quarter.

So I'd keep the Sell, but deeper than proposed. Size the remainder against a 30% stress, finish the trim by a fixed date, and never let a pre-print add take the position above the gap-budget size.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I'll start with what I'm giving up, since this has mostly converged. I accept the lesser-of rule. I accept the 650-660 limit for the second half, because waiting for 677 means carrying excess just to ask for another 10%. I accept five trading days before the print if the date is confirmed, and October 21 if it isn't. I accept three tests instead of four, and I've dropped weak guidance alone as a full exit. Neutral is also right that I can't know the budget lands at the low end. If standard is 5% of the portfolio, 40% of that passes easily and I'd be fine.

Here is where I still push. Aggressive, you called this an exit by committee, and that doesn't fit the plan. It keeps a real position through a print at 126x with no consensus, guidance or date in front of us. Most of the last round's concessions also went your way: the half-now sale, the 650 limit, and no zero. What I won't accept is sizing the remainder by how much we'd like to participate instead of by what we can lose.

Neutral, you say that if size is the only protection, the pure argument is zero. I disagree, for two reasons. We could be wrong about the valuation call, and the remainder is how we insure against our own error. Also, the bull's own bracket runs from minus 17% to plus 10%, so its midpoint is a little worse than minus 3%. The remainder isn't there because holding it has positive expected value on that math. It's there for the trend and for humility, which justifies a modest position. So when 30-40% of standard and the budget disagree, nobody should round up.

Aggressive, you also say a clean print may gap up and you'd be rebuying higher. That's true, and it's the price of the protection. It works like an option premium: known, bounded, and paid on the part we sold. The loss it insures against is larger and limited only by the size we choose.

On options, I'm glad to see it priced, but I'd hold it to the same standard as everything else. A put spread's protection stops at the lower strike, so a 30% gap that goes through it leaves us exposed again. Premium going into earnings on a stock that moves about 3.9% a day will be rich, and the premium is a cost to count, not a freebie. The hedge also has to be bought before the print, not planned. Until there's a real quote in hand, the budget size is the size. The tax treatment of a collar is a separate check.

One mechanical point nobody has made: the report comes after the close and the reaction happens at the open. Every post-print rule, like halving on weak guidance or exiting on weak guidance plus another failure, executes after the gap. Those rules do their job of deciding what the remainder becomes, but they don't protect the first move. So size the remainder as if they didn't exist.

Finally, 616 is yesterday's close. The first half shouldn't depend on getting 616. If it opens lower, the sale is still right, because the reason for it is the size we carry into the print, not the price. Use a limit a bit below the last close so it actually fills, and sell the highest-basis lots first.

So my plan is to sell about half the trim now. I finish on the 650-660 limit, a close below both 599.43 and 596.07, or the deadline, whichever comes first. The remainder is the lesser of 30-40% of standard or what passes a 1% budget at a 30% stress. Nothing is added before the print, the core exits on a 558 close, and there's no re-entry before the print.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: I'll start with what I'm taking from both of you, because most of it is right. Aggressive, you're right that the premium is bounded but not known, and that "acceptable" is the honest word for it. I'll also take your 8% and 11% thresholds. Making the budget checkable is useful because it lets whoever holds this see which side of the rule they're on. Neutral, you're right that the bull's bracket is two chosen multiples, not an expected return, so I'll stop treating its midpoint as a forecast. What it shows is that the stock has no margin of safety, and nothing in the packet offsets that. I'm also fine with confirming the date this week, with Oct 21 as the fallback only if it's still unconfirmed by mid-October.

My remaining disagreement is with the scale-back at "whatever price the market gives us." Having a rule now is better than improvising after a gap, and I agree with that part. But look at what a clean pass does to the valuation. A 18.5% margin on revenue up 9 or 10% is about $2.3B of operating income, or roughly $9.3B annualized. If the stock gaps to 700 on that, the multiple is still about 120x, versus 126x today. A clean print confirms the quarter. It doesn't make the stock cheaper, so the reason we trimmed is still there when we'd be buying back. That supports staged re-entry, not a pre-committed march to 75-100% of standard.

I'd tighten it in three ways. First, a pass has to include DSO and the cash-flow picture, not just margin and guidance. Your example only mentions margin and guidance, but Q2's weak spots were receivables, payables and free cash flow, and a headline beat can still hide a payables reversal. Second, each stage should have to hold its post-print gap for more than a few sessions, since a 3.9% daily mover can give back a gap quickly. Third, and this is the main point, the gap budget doesn't expire after the print. If standard is 10% of the portfolio, 75% of standard is 7.5%, and a 30% gap on that costs more than twice the budget. Every stage has to pass the same lesser-of test, and the budget only loosens if the multiple resets or a second clean quarter arrives.

I'd also change how the budget gets applied. A 1% budget on AMD alone assumes AMD is the only thing that falls on a bad print. If the book also holds other AI or semiconductor names, a 30% AMD gap probably comes with losses elsewhere. The caller should apply the budget to that whole cluster, not to this ticker. We don't have their holdings, so I'd say so explicitly and not leave the 3.3% number looking cleaner than it is.

One thing the plan still underweights is the stretch between now and the deadline. If we sell half the trim now, we're carrying roughly 65-70% of standard for about three to four weeks, which is above the budget the whole debate has been built around. The July slide happened with no earnings event, and the macro headlines include hawkish Fed commentary and a possible long-yield spike. I'm not changing the triggers. A close below both 599 and 596 should handle a slide, since it would fire within a day or two of a drop like July's. But that interim exposure only works if the first tranche really gets done now with a limit that fills, and not "near 616."

On options, I agree with looking early, since the hedge costs more once implied volatility builds. But a hedge bought early covers more time than we need, and until there's a real quote it doesn't change the remainder's size. I'd also keep the macro headlines light. Nothing in the plan hangs on them.

The settled plan stays as is: half the trim now at a limit that fills with the highest-basis lots first, the finish on the first of the 650-660 limit, a close below both 599.43 and 596.07, or the deadline, the remainder at the lesser of 30-40% of standard or the 30%-stress budget, the core exited on a 558 close, and no adds or re-entry before the print. My only changes are that the scale-back be staged, tied to all three tests including DSO and cash flow, and capped by the budget at every step, and that the budget be applied across the whole AI cluster.

FINAL TRANSACTION PROPOSAL: SELL Conservative Analyst: Most of this has converged, so I'll say where I agree and then push on four places where I think the post-print plan is still looser than it looks.

Aggressive, you're right that a scale-back rule written now beats improvising at the open after a gap. You're also right that if the cap never moves, "scale toward 75-100%" is decoration. I accept that a pass can raise the cap, and I appreciate you saying plainly that a standard position above about 5% of the book won't be rebuilt for months. I'll also agree that a close below 596.07 is the only trigger that matters, since it's already below 599.43.

My first disagreement is the cap. You say moving to 5% isn't loosening the budget because 5% times the 22% July slide is about 1.1%. But the stress we agreed on was 30%, and the reason was that 22% happened when the stock was far cheaper. Your own arithmetic puts the multiple at roughly 120x after a clean pass, so nothing has changed that justifies a lower stress. At the same stress, going from 3.3% to 5% is a 50% bigger budget, from 1% to 1.5% of the portfolio. Neutral's argument that the known event is behind us is also weaker than it sounds. The next print is about three months away, so the event risk has been rescheduled, not removed. I can live with 5% as a ceiling, but not as an entitlement. The first stage should be a partial step, and the rest should wait for the cash-flow and DSO qualifier to pass.

Second, the forward-multiple argument has already been counted. Neutral says 120x annualized is a floor for a company growing about 50%, and that guidance shows how far the forward multiple sits below it. But the bull's $17 EPS is that forward view, and at 616 it's about 36x, right in the middle of the 30-40x bracket. A clean pass confirms the bracket's earnings. It doesn't raise them. Only guidance well above trend does that, so guidance has to be the test that earns the larger stages.

Third, the hold condition is too easy. If the stock gaps from 616 to 700 and then slides back to 620, it has held above the pre-print close for three sessions while giving back almost the whole gap. A stock that does that after a clean print is telling us something. I'd require stage one to hold the upper half of the gap, or the post-print low if that's higher, and to stay above the 10 EMA. If it fails, we wait, and 510-530 becomes a legitimate structural entry again, as you said.

Fourth, the execution details. A sell limit around 604 is a floor, and it protects the sale price, not the sale. If it doesn't fill, the stock is already trading below 604, which is when we most need to be done. "Reprice if it doesn't fill within two sessions" has to mean go to market, not wait for a bounce. The sale doesn't depend on getting 616, so a few dollars of slippage is cheap. I'd also drop the claim that AMD carries the worst multiple in the cluster. The packet gives us no data on any other holding. We know AMD is expensive, not that it's the most expensive thing in the book.

My plan is mostly unchanged. Sell about half the trim now, with a limit that fills or at market. Finish at the first of the 650-660 limit, a close below 596.07, or five trading days before a confirmed print, with October 21 only if the date is still unconfirmed by mid-October. Size the remainder at the lesser of 30-40% of standard or the 1% budget at a 30% stress, applied across the whole AI and semiconductor cluster. Exit the core on a 558 close, add nothing before the print, and re-enter nothing before it. After the print, count three tests. Weak guidance halves the remainder, and weak guidance plus another failure exits it. A pass rebuilds in held stages, capped at about 5% only if guidance is clearly above trend and DSO and cash flow qualify, and the budget still applies at every step.

FINAL TRANSACTION PROPOSAL: SELL

Neutral Analyst¶

Neutral Analyst: You've both spent your openings on a neutral case I'm not making. I'm not saying hold everything and wait for the print. The trim is right. But each of you has a weak spot that changes how it should be done, so let me go through them.

The aggressive analyst's strongest line is "re-rating, not an earnings story." The 14% comes from measuring against the Q4 print, which is one window. Against Q3 of last year, operating income is up about 57%, and revenue is up 50% year on year. The stock also prices forward estimates, and we have no consensus, guidance or company news. The 09-21 gap came on 44.5M shares, the heaviest volume in two months, which looks like news we can't see. At about a trillion dollars of market cap and under a 1% free cash flow yield, the stock is clearly expensive. But that doesn't show forward numbers stayed put. The conservative is also right that 40x on $17 gives about 680, so plus 10%, not low single digits. Minus 17% to plus 10% centers near zero. That argues for a smaller position, not no position.

The same goes for "three of four tests failing today." Operating margin is gross margin, less R&D and SG&A, less about 2.4 points of Xilinx amortization. That reconciles to the reported $1.99B. If gross margin holds near 54%, opex under 33% of revenue is roughly an 18.5-19% margin, so those two tests are nearly one. If the exit rule is "two or more fail," one cause can trigger it twice. Passing also looks attainable. If opex grows about 6%, you need roughly 9-10% sequential revenue growth. That was cleared in three of the last four quarters, and the fourth was flat. So the bar is attainable but unforgiving, and at this price passing is the entry ticket, not a catalyst.

To the conservative, the asymmetry math is right, but the scenarios are chosen. Plus 10% against minus 20% implies a two-thirds breakeven, and a different pair gives a different answer. Your best point is that size is the only protection through a gap. But 15-25% versus 30-40% of a standard allocation can't be settled without knowing what standard means. So size the remainder with a gap budget: a 25% gap should cost about 1% of the whole portfolio or less, which means a remainder of at most about 4% of the portfolio. If 30-40% of standard passes that test, keep it. If not, go lower, even to your range.

Your 599/596 trigger is about 0.7 ATR from the price, and the technical report says stops under 1.5-2 ATR get hit by noise. That's fine as a second-tranche trigger but bad for dumping the remainder. "Weak guidance alone exits everything" is too mechanical at this multiple, since the stock can fall on fine guidance and rise on one soft metric. "We can rebuy after a clean print" also understates the cost, because a clean print at 126x may gap up. And in a taxable account with a low basis, selling 80% is a real cost.

The aggressive plan doesn't work "whichever way the print goes" either. If the stock runs to 700 and never touches 510-530, you're adding after the print at higher prices. The plan also has a contradiction. A close below 558 exits the core because the trend is broken, but the add at 510-530 then buys back 60% of standard, larger than the core you just sold. It also says "no adds before the print" and "add at 510-530" in the same breath. Before the print, any add should be capped at the trimmed size.

On the technicals, ADX falling from a burst peak is normal, and it's still above 25. RSI is 67, MFI is under 80, daily z is near zero, and OBV is near its high. The monthly TD count of 7 can't complete before late November, after the likely early-November report, which is unverified. These say extended, not "sell by Friday." The macro headlines are headline-only and conflict, so I'd weight them lightly.

My proposal is to stay with the Sell, as a staged trim to 30-40% of standard, or less if the gap budget demands. Sell about half of the trim now, since 616 is already in the plan's selling zone. Sell the rest on a close below both 599 and 596, or into strength above the old high toward the upper band near 677, whichever comes first. Keep the 558 close as the exit for the core. After the print, count margin and opex as one test. Weak guidance cuts the remainder in half, and weak guidance plus any other failure exits it. A clean pass lets you scale back toward 75-100% in stages. Neutral Analyst: You've both moved enough that most of what's left is parameters, so let me say where I land and push on the few places where I think you're each still off.

First, what's settled. It's a trim, not an exit. The core stays under a 558 close. We count three independent tests, with margin and opex as one. Weak guidance halves the remainder, and weak guidance plus another failure exits it. Re-entry is earned by the print, not by a price level. Conservative is right on that last point, and I'll go further. If the 558 close triggers, don't re-enter before the print at all. And before the print, nothing gets added above the gap-budget size. Aggressive, capping adds at the trimmed size would let you buy the whole trim back at 510-530 and walk into the event at full size. That was a fair catch.

Now the sizing fight, which I think is smaller than it looks. Conservative wants a 30% stress and Aggressive is comfortable at 25%. On a 1% portfolio budget that's 3.3% versus 4%, a difference of about 0.7 points of portfolio. I'd take 30%. The July slide was 22% when the stock was far cheaper, the lower band is 29% below price, and the multiple is 126x. But Conservative, you then say the answer should land at the low end or below. You can't know that. We don't know what a standard allocation is. The rule should be a minimum: the remainder is the lesser of 30-40% of standard and the budget divided by the stress. A 5% standard position passes easily, and a 15% one doesn't. The 1% budget is also a preference, not a fact, so don't treat the result as more precise than it is.

There's also a logical point for Conservative. You say the post-print rules do nothing for the first move, and that's true. But if size is the only protection and we have no edge on the print, the pure version of that argument is zero. You aren't arguing for zero, because the trend is intact and the bracket is roughly flat, not clearly negative. Given that, the question is only how much, and the budget answers it. The post-print rules aren't there to stop the gap. They decide whether the remainder becomes an add or an exit afterward.

I'd also like an input nobody has used: the options-implied move for the print. The packet has none, so I can't quote it. But once the date is confirmed, it's a much better anchor for the stress case than our guesses of 25% or 30%. It also opens a middle path. A collar or put spread on the core would cover the gap risk Conservative worries about without forcing a deeper sale. That helps Aggressive on the clean-print and tax points. I can't say whether it's affordable at this volatility, so check it before relying on it.

On staging, I'll concede Conservative's point about the 599/596 trigger. My ATR objection applies to stops on the core, not to finishing a trim to a size we've already chosen. But I don't like waiting for 677, which is a 10% rally just to sell. Put a limit on the second half closer to 650-660, just above the 639 intraday high. Then use whichever comes first: that limit, a close below both 599 and 596, or a date. Dates are checkable. Companies normally announce earnings weeks ahead, so confirm it now. Use five trading days before the report if it's confirmed, and about October 21 if it isn't. Sell the highest-basis lots first. Conservative is right that taxes are mostly a timing cost and a reason for lot selection, not for carrying risk.

Aggressive, one more push. "Stock up 2.9x, operating income up 14%" still uses a single window. Against Q2 last year operating income went from a loss of $134M to $1.99B. That doesn't make the stock cheap, since the trailing P/E is about 158x at 616 and the free cash flow yield is under 1%. But the conclusion should rest on valuation, not on that comparison. Also, the 44.5M-share day cuts both ways. We can't tell whether it was news, so it shouldn't move anyone's size in either direction.

So my plan: sell about half the trim now near 616, finish by the rules above, and size the remainder by the minimum rule. Hold the core under 558, add nothing before the print above the budget size, and let the print decide any scale-up.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the gap-budget size, with the core held under a 558 close. Neutral Analyst: I think we're down to a few disagreements, and each of you is still overreaching a little.

Conservative, you now call the bull's bracket's midpoint "a little worse than minus 3%." That bracket is two multiples someone picked, 30x and 40x, applied to a $17 EPS estimate. Its midpoint is the middle of two assumptions, not an expected return. The stock has traded at far higher multiples than that, and nothing in the packet says it can't hold them. The bracket tells us the valuation gives no margin of safety, and I agree with that. It doesn't tell us the expected return is negative. The same goes for your "insurance against our own error" argument for the remainder. It's fair, but it supports a modest position, not a precise one.

Aggressive, I'd retire the "exit by committee" line. A plan that keeps a budgeted position through a print at about 158x trailing earnings, with no date, no guidance and no consensus in hand, isn't an exit. The remainder is small by construction. Calling it the bold, contrarian part overstates it. Its job is to keep us in the trade if the market keeps paying up, and nothing more than that. If a clean print gaps the stock 15% higher, a budget-sized remainder gains little, and we should accept that now. The fair reply to Conservative's insurance analogy is that the premium is bounded, but nobody here has an edge to say the bad event is likely enough to justify a bigger premium than the one we're already paying.

Conservative, you're right that the report comes after the close and the open is the first tradable price. I'd take that further. A close below 558 is also a daily-close rule, so a gap through it exits at the gap price, not at 558. That's why the budget has to be set against the 30% stress, not against the distance to the stop.

On the date, the packet says only "late October or early November." Oct 21 as a fallback means we might sell a week or two earlier than needed. That's an acceptable cost for a rule that can't be talked out of. It's also checkable, since companies announce dates weeks ahead. I'd confirm it this week so the fallback rarely gets used.

On execution, I agree with Conservative that the first half should be a limit that fills, not a bet on 616. I'd sell the highest-basis lots first, and check holding periods in case any lots are short-term.

On options, you've both stated the right cautions. The implied move is an expected move, not a tail. A put spread stops protecting below its lower strike. A tight collar on an appreciated position may be a constructive sale for tax purposes. Until there's a quote, the budget size is the size. If a hedge prices reasonably, it can justify a bit more than the budget, but only after it's bought.

My plan:

Sell about half the trim now with a limit that fills.
Finish on the first of these: a 650-660 limit, a close below both 599.43 and 596.07, or five trading days before a confirmed print (about October 21 if it's unconfirmed).
Size the remainder as the lesser of 30-40% of standard or what a 1% portfolio budget allows at a 30% stress, which is about 3.3% of the portfolio.
Exit on a daily close below 558.
Add nothing and re-enter nothing before the print.
After the print, count three tests, with margin and opex as one. Weak guidance halves the remainder, weak guidance plus another failure exits it, and a clean pass scales back in stages toward 75-100%.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the remainder exited on a daily close below 558. Neutral Analyst: We're now arguing about what happens after the print, which is a good sign, because the pre-print plan is basically done. Let me take the two open disputes and then say where I'd land.

Aggressive, you're right that a rule written now beats improvising at the open after a gap, and that anchoring on our 616 sale price is a real failure mode. But "scale back at whatever price the market gives us" only fixes the anchoring half of the problem. Your example had margin and guidance passing. Q2's weak spots were receivables, payables and free cash flow, and neither of those two tests covers them. Conservative is also right on the arithmetic. At 18.5% margin on revenue up 9-10%, operating income is about $2.3B, or $9.3B annualized, and a gap to 700 puts the stock at roughly 120x against 126x today. A clean print confirms the quarter but doesn't make the stock cheap. Your option analogy also has a hole. A print passing doesn't mean the stock is worth more after it gaps 15%, so the first stage back should be modest, not a march to full size.

Conservative, your 120x is one quarter annualized, which is a floor for a company growing revenue about 50% a year. If guidance is above trend, the forward multiple is lower than that by an amount none of us can know yet. That is exactly why guidance is a test.

Then there's "the budget never expires." Taken literally, a 1% budget at a 30% stress caps the position at about 3.3% of the portfolio. Scaling toward 75-100% of standard is then only reachable if standard is under about 4% of the book. For almost anyone, the original scale-up language becomes decoration. Either we mean it or we drop it. My middle path is that after a clean pass the known event is behind us, so the cap can rise to about 1.5% of the portfolio at the same 30% stress, which is roughly 5%. That isn't a zero-risk number, because July's 22% slide had no catalyst at all. Anything beyond that waits for a second clean quarter or a multiple reset.

On what counts as a pass, I'd keep three tests but treat cash flow as a qualifier. A $2.3B payables swing makes one quarter of free cash flow noisy. If FCF is down only because payables unwound while DSO improved, that's a watch item. If DSO is still climbing and operating cash flow ex-payables is weak, stage two is blocked. For holding conditions, I'd buy stage one after the stock holds above its pre-print close for three sessions, and stage two after another week above the post-print low. If the stock falls on a clean print, we wait, and 510-530 becomes a legitimate structural entry again.

I agree with Conservative that the budget should be read against the whole AI and semiconductor cluster. That's a caveat for the caller, not something we can put a number on, since we don't know their book.

The interim exposure is Conservative's best new point, but I'd answer it carefully. Carrying roughly two-thirds of standard for three to four weeks is a different risk from the print. It's non-event drawdown, and that's what the 599/596 trigger covers, only about 3% below price. What it can't cover is an overnight macro gap, which we accept for a bounded window. That only works if the first tranche really fills, so use a limit within about half an ATR of the last close, not a hope for 616.

On options, get a quote this week to learn the price. Buy only once the date is confirmed and the expiry sits just after the print, and don't let a hedge change the size until it's actually bought.

So my plan is to sell about half the trim now with a limit that fills, highest-basis lots first. Finish on the first of the 650-660 limit, a close below both 599.43 and 596.07, or five trading days before a confirmed print (about October 21 only if the date is still unconfirmed by mid-October). Size the remainder at the lesser of 30-40% of standard or what a 1% budget allows at a 30% stress. A standard position under about 8% of the portfolio passes the whole range, and above about 11% the budget sets the size. Exit the core on a daily close below 558, add nothing and re-enter nothing before the print, and treat the 558 trigger as a close-based rule that executes at the next open. After the print, count three tests. Weak guidance halves the remainder, weak guidance plus another failure exits it, and a clean pass rebuilds in stages under the 1.5% cap.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the remainder exited on a daily close below 558 and a staged, budget-capped scale-back only if the print earns it. Neutral Analyst: We're close enough that I'll go straight to the four places where I think each of you is still a little off.

Conservative, you're right that I changed the budget and not the stress. Moving from 1% to 1.5% of the portfolio is a real loosening, and Aggressive's 5% times the 22% July slide framing hides that. I'd defend it on a different basis. The 3.3% cap exists because a print is scheduled inside the window. After a clean print, the next one is about three months out, so the chance of a 30% drop over the holding period is lower, even though the size of that drop if it happens is the same. A budget can reasonably rise when the probability falls. I won't claim the stress changed, because a stock at roughly 120x could do another July with no catalyst at all. So 5% is a ceiling, and the first stage should sit well below it. You're also right that the forward-multiple argument was already counted. At 616, the bull's $17 EPS is about 36x, so a clean quarter confirms the bracket and doesn't widen it. Only guidance moves the earnings estimate, and it can move it either way. So stage one needs a held gap and a pass on margin and opex, and stage two, the move toward the cap, needs guidance clearly above the recent sequential trend and the DSO and cash-flow qualifier to clear. We have no consensus, so define "above trend" against the last four quarters of sequential growth, roughly 11% and 12.5% in the two quarters that grew, with one flat quarter in between. Without that definition, the guidance test becomes whatever the stock did on the day.

I mostly agree your hold condition is better than three sessions above the pre-print close, but parts of it don't work. Staying above the 10 EMA is nearly free after a gap. If the stock jumps 15%, the EMA will sit far below price for days, so it filters almost nothing. The half-gap rule is good on a big gap and too tight on a small one. On a 5% gap to about 647, the midpoint is only about 2.5% below the high, which is well under one ATR and is just noise on a stock that moves 3.9% a day. So I'd require stage one to hold above the post-print low and the pre-print close, plus the gap midpoint when the gap is larger than about 1.5 ATR, roughly 6%. On smaller gaps, the post-print low is the test.

On execution, you're right that a limit near 604 protects the price and not the sale. If it hasn't filled by the second session, the stock is already below it, which is when we most want to be done. Sell at market, and not in the first minutes of the open. For a name this liquid, a few dollars of slippage is cheap compared with the risk we're trimming. You're also right to drop the claim that AMD is the most expensive name in the cluster. The packet says nothing about any other holding. We know AMD is expensive, and nothing more.

Aggressive, I think you're still holding on to something you've already conceded in substance. You said the bold part is after a clean print, and that's fine. But the first stage back is modest, it waits on evidence and a hold, and it's capped by the budget. At that point the plan stops being a bold re-entry and becomes a staged rebuild. That's the right design, and you should call it that. Your concern about anchoring on the 616 sale price also cuts the other way. Stock gapping to 700 on a clean print is still around 120x annualized on one quarter, and nothing about the price we sold at changes that. We shouldn't refuse to buy at 700, and we shouldn't feel obliged to either.

Both of you are treating the interim as a footnote, and I'd keep it in view. Selling half the trim now leaves us with about two-thirds of standard for three to four weeks. A July-style 22% slide on that costs about 15% of the position, which is meaningful if a standard allocation is large. The close below 596.07 is the protection, and it's only about 3% away. It doesn't cover an overnight macro gap, and I'd be honest that we're accepting that for a bounded period. It also means the first tranche, and then the second one by the deadline, can't slip. Confirm the earnings date this week. If the packet's "late October or early November" turns out to be November, the five-trading-days-before rule keeps us from selling earlier than we need to, and October 21 applies only if the date is still unconfirmed by mid-October.

What the packet doesn't tell us still matters more than any of these parameters. We have no sentiment data, no company news, no consensus, no verified date, and no idea what the caller holds. I'd weight the macro headlines lightly: the 10-year-at-a-multi-decade-high line is unconfirmed, and yields fell on 10/1. The plan has to be sized to the caller's own standard allocation, with the cap applied across any other AI and semiconductor exposure they have, and not to a number we guessed.

So here's where I land. Sell about half of the trim today, with a limit that fills and a switch to market if it doesn't by the second session, highest-basis lots first, and check holding periods. Finish the trim on the first of a 650-660 limit, a close below 596.07, or five trading days before a confirmed print, with about October 21 only if the date is still unconfirmed by mid-October. The remainder is the lesser of 30-40% of standard or what a 1% portfolio budget allows at a 30% stress. That passes the whole range if standard is under about 8% of the book, and above about 11% the budget sets the size. Exit the core on a daily close below 558, executed at the next open. Add nothing and re-enter nothing before the print. After the print, count three tests, with margin and opex as one. Weak guidance halves the remainder, and weak guidance plus another failure exits it. A clean pass lets us rebuild in two held stages. Stage one is modest and needs a margin and opex pass and a gap that holds. Stage two needs guidance clearly above trend and a DSO and cash-flow qualifier, and can reach a ceiling of about 5% of the portfolio. Anything above that waits for a second clean quarter or a reset in the multiple. If the stock falls on a clean print, we wait, and 510-530 around the 50 SMA is a legitimate structural entry again, not a value entry.

FINAL TRANSACTION PROPOSAL: SELL, as a staged trim to the lesser of 30-40% of standard or the 30%-stress gap budget, with the remainder exited on a daily close below 558 and a staged, budget-capped scale-back only if the print and the hold both earn it.

V. Portfolio Manager Decision¶

Portfolio Manager¶

Rating: Underweight

Executive Summary: Cut AMD to a reduced core, carried through the Q3 print. Sell about half of the planned trim now with a limit that will fill near 604 or better, and switch to a market order if it hasn't filled by the second session. Sell the rest at the first of three triggers: a 650-660 limit, a daily close below 596.07, or five trading days before a confirmed print (Oct 21 if the date is still unconfirmed by mid-October). The remaining position should be the smaller of 30-40% of your standard allocation or the size at which a 30% gap costs about 1% of the portfolio. Count all AI and semiconductor holdings toward that limit. Exit the remainder on a daily close below 558, and add or re-enter nothing before the print. Horizon is 1-3 months, through the Q3 print and its aftermath.

Investment Thesis: The research plan, the trader and all three risk analysts end up in the same place: reduce, don't exit. What they disagreed on was how much and how, not which direction. So the rating is Underweight, not Sell (which means a full exit) and not Hold.

Why reduce. The stock is up 193% since April (210.21 to 615.73). Most of that came from a higher multiple, not higher earnings. Annualized operating income was valued at about 49x then and about 126x now. Trailing P/E is about 158x and the FCF yield is under 1%. The bull's own forward case of about $17 EPS at 30-40x gives roughly 510-680, or -17% to +10%. The Aggressive analyst first said +2.5% a year at 40x, but the Conservative analyst corrected that to about 680 and the Aggressive analyst accepted it. Even the optimistic case leaves no margin of safety. At 616 the stock already trades at about 36x that forward EPS, so a clean quarter only confirms the range. Only guidance well above trend would move it. Earnings quality is mixed: - About $2.27B of payables propped up roughly $2.4B of Q2 operating cash flow. - DSO rose from 54 to 57 days. - FCF fell 39% quarter on quarter as capex doubled. - Buybacks of $207M did not cover $503M of stock compensation. - Q2 EPS was lifted by a $483M investment gain and a 9.8% tax rate. The technicals show a late-stage stretch: weekly z-score +2.14, monthly TD count -7 of 9, ADX down from 43.11 to 29.41, MFI about 76, and price 20% above the 50 SMA and 65% above the 200 SMA.

Why not exit. Revenue grew about 50% year on year to $11.54B. Operating margin is at a cycle high of 17.3%, gross margin is steady at 52-54%, and net cash is about $8.8B. The trend is intact: all three SuperTrends point up, price is above the 10 EMA, 50 SMA, 200 SMA and VWMA, and OBV is near its high with no divergence. The 09-21 breakout ran on 44.5M shares. The Neutral analyst made the point that settled it. If position size is the only protection and we have no edge on the print, the logical end of that argument is zero. But the valuation range is roughly flat, not clearly negative, so the real question is how much to hold. A gap budget answers that better than argument.

How the debate shaped the plan. The Conservative analyst made the strongest points on mechanics: - Stops don't protect through an earnings gap. The report lands after the close, and the 558 rule only executes at the next open. - The stress case should be 30%, not 25%. July fell 22% with no catalyst and at a lower multiple. - A price-only re-entry at 510-530 before the print would put you back at full size into the event you just trimmed for. - A limit order protects the price, not the sale. The Neutral analyst supplied the lesser-of sizing rule and caught two contradictions in the original re-entry plan. Margin and opex are nearly one test, so there are three tests, not four. Neutral also noted that a 10 EMA filter does little after a gap. The Aggressive analyst was right that a scale-back rule written now beats improvising, and that refusing to buy above our sale price would be anchoring. The plan keeps that, but as staged rebuilding capped by the budget, not a promise to return to full size.

Sizing check. The 1% budget at 30% stress caps the remainder at about 3.3% of the portfolio. If your standard AMD allocation is under about 8% of the book, the whole 30-40% range fits. Above about 11%, the budget sets the size. Note that between now and the deadline you'll still hold about two-thirds of a standard position. That interim risk is covered only by the 596.07 trigger, which is about 3% away and doesn't protect against an overnight macro gap.

After the print, three tests: 1. Margin and opex: operating margin above 18-19%, with R&D plus SG&A below 33% of revenue. 2. Guidance implying sequential growth above the recent trend of about 11-12.5%. 3. DSO back toward 54 days and operating cash flow ex-payables holding up, used as a qualifier.

Actions: - Weak guidance: halve the remainder. - Weak guidance plus any other failure: exit. - Clean pass, stage one: a modest add once the gap holds above both the post-print low and the pre-print close. If the gap is larger than about 6%, it must also hold the gap midpoint. - Clean pass, stage two: requires the guidance and cash-flow tests to pass. Cap total exposure at about 5% of the portfolio until a second clean quarter or a reset in the multiple. - If the stock falls on a clean print: 510-530 near the 50 SMA becomes a reasonable entry on chart structure, not on value.

What would change the call. Toward Overweight: strong guidance with segment or data-center detail that lowers the forward multiple, or a pullback to about 510 with the thesis intact. Toward Sell: a daily close below 558, two failed tests, or adverse export-control news.

Data gaps. The packet has no guidance, consensus, segment mix, customer concentration, export-control status, sentiment, confirmed earnings date or options-implied move. The macro headlines are unconfirmed. Holdings weren't given either. These gaps limit confidence in both directions.

Current Price: 615.73

Price Target: 510.0

Confidence: Medium

Time Horizon: 1-3 months